Id	Position	Residue	Bepipred2	Emini	Parker	Chou Fosman	Karplus Schulz	Kolaskar	MW	IP	Hydropathy
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	1	V	0.23	0.00	0.00	0.00	0.00	0.00	117.15	5.49	4.20
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	2	R	0.27	0.00	0.00	0.00	0.00	0.00	174.20	9.75	-4.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	3	S	0.31	0.23	0.00	0.00	0.00	0.00	105.09	5.24	-0.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	4	L	0.33	0.45	1.63	1.03	0.98	1.09	131.17	5.52	3.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	5	N	0.39	0.19	0.84	1.04	0.97	1.07	132.12	5.52	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	6	C	0.40	0.28	0.84	1.04	0.96	1.07	121.15	5.52	2.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	7	T	0.41	0.56	1.34	1.04	0.96	1.05	119.12	5.19	-0.70
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	8	L	0.42	0.47	3.59	1.16	0.99	1.01	131.17	5.52	3.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	9	R	0.44	1.50	3.44	1.08	1.03	1.05	174.20	9.75	-4.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	10	D	0.45	1.80	4.10	1.05	1.07	0.99	133.10	3.80	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	11	S	0.46	4.37	4.17	1.06	1.11	0.99	105.09	5.24	-0.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	12	Q	0.45	2.99	6.41	1.18	1.12	0.96	146.15	5.52	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	13	Q	0.45	1.48	4.50	1.13	1.12	1.01	146.15	5.52	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	14	K	0.43	0.82	2.54	0.99	1.08	1.09	146.19	8.75	-3.90
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	15	S	0.43	0.47	1.01	0.87	1.03	1.06	105.09	5.24	-0.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	16	L	0.43	0.36	1.09	0.93	0.99	1.06	131.17	5.52	3.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	17	V	0.42	0.18	1.04	1.02	0.97	1.04	117.15	5.49	4.20
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	18	M	0.42	0.21	0.53	1.09	0.98	1.06	149.21	5.28	1.90
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	19	S	0.41	0.39	-0.67	1.05	1.01	1.08	105.09	5.24	-0.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	20	G	0.39	0.92	1.76	1.07	1.03	1.02	75.07	5.52	-0.40
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	21	P	0.41	0.76	0.97	1.08	1.03	1.01	115.13	5.96	-1.60
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	22	Y	0.42	1.14	2.39	1.14	1.01	1.02	181.19	5.52	-1.30
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	23	E	0.43	1.16	1.76	1.03	0.99	1.03	147.13	4.00	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	24	L	0.43	0.62	-0.37	0.89	0.98	1.08	131.17	5.52	3.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	25	K	0.43	0.54	-0.37	0.81	0.97	1.09	146.19	8.75	-3.90
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	26	A	0.44	0.26	-1.41	0.73	0.96	1.10	89.09	5.57	1.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	27	L	0.46	0.54	-1.67	0.77	0.95	1.12	131.17	5.52	3.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	28	H	0.48	0.27	0.46	0.91	0.96	1.07	155.16	6.74	-3.20
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	29	L	0.52	0.46	0.50	0.90	0.99	1.08	131.17	5.52	3.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	30	Q	0.54	0.92	1.63	1.02	1.03	1.05	146.15	5.52	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	31	G	0.58	0.67	2.34	1.02	1.07	0.99	75.07	5.52	-0.40
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	32	Q	0.59	1.41	3.16	0.99	1.08	0.96	146.15	5.52	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	33	D	0.61	1.41	5.33	1.04	1.08	0.92	133.10	3.80	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	34	M	0.60	2.47	5.33	1.04	1.06	0.92	149.21	5.28	1.90
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	35	E	0.58	1.06	3.99	0.89	1.05	1.00	147.13	4.00	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	36	Q	0.54	0.47	2.60	0.82	1.04	1.05	146.15	5.52	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	37	Q	0.51	0.41	-0.14	0.70	1.01	1.08	146.15	5.52	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	38	V	0.47	0.32	1.39	0.82	0.98	1.11	117.15	5.49	4.20
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	39	V	0.46	0.18	-0.33	0.80	0.95	1.10	117.15	5.49	4.20
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	40	F	0.44	0.14	-0.26	0.86	0.93	1.10	165.19	5.52	2.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	41	S	0.42	0.16	-2.43	0.81	0.92	1.11	105.09	5.24	-0.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	42	M	0.41	0.16	-2.43	0.81	0.93	1.11	149.21	5.28	1.90
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	43	S	0.44	0.33	-1.04	0.88	0.93	1.06	105.09	5.24	-0.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	44	F	0.46	0.24	1.09	1.01	0.95	1.03	165.19	5.52	2.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	45	V	0.50	0.43	1.27	0.92	0.98	1.01	117.15	5.49	4.20
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	46	Q	0.53	0.55	2.99	0.94	1.02	1.01	146.15	5.52	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	47	G	0.55	0.85	2.99	0.94	1.07	1.01	75.07	5.52	-0.40
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	48	E	0.56	1.84	5.30	1.07	1.10	0.97	147.13	4.00	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	49	E	0.58	1.78	7.26	1.21	1.11	0.89	147.13	4.00	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	50	S	0.58	3.59	7.21	1.21	1.11	0.88	105.09	5.24	-0.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	51	N	0.56	1.45	5.26	1.06	1.10	0.92	132.12	5.52	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	52	D	0.52	1.30	4.44	1.17	1.07	0.95	133.10	3.80	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	53	K	0.49	0.72	2.80	1.14	1.04	1.03	146.19	8.75	-3.90
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	54	I	0.45	0.45	2.17	1.03	1.00	1.03	131.17	5.52	4.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	55	P	0.42	0.22	-0.14	0.89	0.97	1.10	115.13	5.96	-1.60
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	56	V	0.39	0.11	-0.76	0.90	0.94	1.10	117.15	5.49	4.20
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	57	A	0.39	0.13	-2.89	0.84	0.93	1.15	89.09	5.57	1.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	58	L	0.39	0.17	-0.93	0.92	0.94	1.12	131.17	5.52	3.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	59	G	0.39	0.39	-0.11	0.81	0.97	1.09	75.07	5.52	-0.40
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	60	L	0.41	0.78	1.23	0.88	1.00	1.02	131.17	5.52	3.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	61	K	0.43	1.51	1.93	1.01	1.03	0.98	146.19	8.75	-3.90
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	62	E	0.44	1.26	1.93	1.01	1.05	0.98	147.13	4.00	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	63	K	0.44	2.39	0.84	0.95	1.04	1.02	146.19	8.75	-3.90
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	64	N	0.44	0.99	0.84	0.95	1.01	1.02	132.12	5.52	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	65	L	0.44	0.76	0.96	1.01	0.97	1.03	131.17	5.52	3.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	66	Y	0.43	0.20	0.04	1.07	0.93	1.11	181.19	5.52	-1.30
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	67	L	0.43	0.09	-1.30	1.00	0.92	1.18	131.17	5.52	3.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	68	S	0.43	0.09	-3.61	0.86	0.91	1.25	105.09	5.24	-0.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	69	C	0.43	0.12	-1.49	0.92	0.92	1.20	121.15	5.52	2.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	70	V	0.43	0.24	0.21	0.97	0.95	1.16	117.15	5.49	4.20
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	71	L	0.44	0.30	2.96	1.09	0.98	1.10	131.17	5.52	3.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	72	K	0.45	1.14	2.84	1.03	1.01	1.09	146.19	8.75	-3.90
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	73	D	0.46	2.37	2.94	1.08	1.03	1.04	133.10	3.80	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	74	D	0.45	4.14	4.21	1.14	1.05	0.97	133.10	3.80	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	75	K	0.45	1.71	4.21	1.14	1.05	0.97	146.19	8.75	-3.90
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	76	P	0.44	1.77	4.26	1.14	1.04	0.99	115.13	5.96	-1.60
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	77	T	0.45	0.87	1.51	1.02	1.01	1.04	119.12	5.19	-0.70
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	78	L	0.46	0.76	1.20	0.91	0.99	1.04	131.17	5.52	3.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	79	Q	0.48	0.66	1.31	0.97	0.98	1.05	146.15	5.52	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	80	L	0.49	0.34	0.49	0.83	0.98	1.10	131.17	5.52	3.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	81	E	0.50	0.68	1.17	0.90	1.00	1.09	147.13	4.00	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	82	S	0.52	0.61	2.79	1.03	1.02	1.06	105.09	5.24	-0.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	83	V	0.55	1.48	2.74	1.04	1.04	1.05	117.15	5.49	4.20
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	84	D	0.56	1.37	5.06	1.17	1.05	0.98	133.10	3.80	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	85	P	0.59	1.61	3.67	1.23	1.05	1.03	115.13	5.96	-1.60
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	86	K	0.59	3.35	3.04	1.24	1.05	1.03	146.19	8.75	-3.90
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	87	N	0.59	4.01	4.39	1.32	1.04	0.97	132.12	5.52	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	88	Y	0.58	5.18	3.77	1.25	1.04	0.98	181.19	5.52	-1.30
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	89	P	0.56	5.18	4.29	1.18	1.05	0.96	115.13	5.96	-1.60
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	90	K	0.55	3.19	2.87	1.12	1.06	0.95	146.19	8.75	-3.90
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	91	K	0.53	3.52	2.99	1.00	1.06	0.96	146.19	8.75	-3.90
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	92	K	0.52	4.56	4.07	0.99	1.06	0.92	146.19	8.75	-3.90
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	93	M	0.51	4.46	4.37	0.90	1.04	0.90	149.21	5.28	1.90
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	94	E	0.49	1.93	2.24	0.85	1.03	0.92	147.13	4.00	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	95	K	0.48	0.72	0.90	0.77	1.02	0.98	146.19	8.75	-3.90
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	96	R	0.46	0.63	-1.23	0.71	0.99	1.01	174.20	9.75	-4.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	97	F	0.45	0.58	0.37	0.85	0.97	1.00	165.19	5.52	2.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	98	V	0.46	0.58	0.07	0.89	0.96	1.01	117.15	5.49	4.20
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	99	F	0.47	0.21	-1.89	0.81	0.96	1.04	165.19	5.52	2.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	100	N	0.49	0.42	-1.37	0.78	0.98	1.04	132.12	5.52	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	101	K	0.50	0.39	-1.20	0.76	1.00	1.05	146.19	8.75	-3.90
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	102	I	0.51	0.73	0.33	0.92	1.00	0.96	131.17	5.52	4.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	103	E	0.54	0.73	2.64	1.05	1.00	0.92	147.13	4.00	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	104	I	0.54	0.73	2.46	0.97	1.01	0.94	131.17	5.52	4.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	105	N	0.56	0.86	0.33	0.91	1.02	0.98	132.12	5.52	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	106	N	0.54	0.86	2.59	0.95	1.03	0.94	132.12	5.52	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	107	K	0.54	1.06	0.16	0.93	1.02	0.98	146.19	8.75	-3.90
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	108	L	0.51	1.15	2.41	0.97	1.00	0.93	131.17	5.52	3.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	109	E	0.49	0.95	2.34	0.95	0.99	0.97	147.13	4.00	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	110	F	0.48	0.48	1.64	0.82	0.99	1.01	165.19	5.52	2.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	111	E	0.47	1.01	1.69	0.82	0.99	1.02	147.13	4.00	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	112	S	0.45	0.51	1.69	0.82	0.99	1.00	105.09	5.24	-0.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	113	A	0.45	0.90	0.87	0.93	0.99	1.03	89.09	5.57	1.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	114	Q	0.42	0.84	3.19	1.07	0.99	0.98	146.15	5.52	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	115	F	0.42	0.66	0.64	1.10	0.98	0.99	165.19	5.52	2.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	116	P	0.39	1.02	-0.56	1.06	0.98	1.01	115.13	5.96	-1.60
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	117	N	0.39	0.41	-2.00	1.03	0.96	1.02	132.12	5.52	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	118	W	0.38	0.64	-1.93	1.10	0.95	1.02	204.23	5.52	-0.90
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	119	Y	0.37	0.60	0.13	1.15	0.94	1.00	181.19	5.52	-1.30
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	120	I	0.38	0.50	0.76	1.14	0.96	0.99	131.17	5.52	4.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	121	S	0.39	0.82	0.61	1.05	1.00	1.02	105.09	5.24	-0.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	122	T	0.41	0.53	2.34	1.01	1.04	1.05	119.12	5.19	-0.70
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	123	S	0.43	1.31	3.73	0.95	1.07	1.00	105.09	5.24	-0.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	124	Q	0.45	1.57	5.87	1.11	1.06	0.95	146.15	5.52	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	125	A	0.47	1.07	4.34	0.99	1.05	0.92	89.09	5.57	1.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	126	E	0.48	1.24	3.90	1.07	1.02	0.94	147.13	4.00	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	127	N	0.49	0.53	2.44	0.94	0.99	1.00	132.12	5.52	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	128	M	0.48	0.46	0.27	0.88	0.97	1.01	149.21	5.28	1.90
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	129	P	0.45	0.22	-1.34	0.87	0.95	1.03	115.13	5.96	-1.60
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	130	V	0.45	0.13	-1.64	0.99	0.94	1.04	117.15	5.49	4.20
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	131	F	0.45	0.13	-1.83	0.99	0.96	1.05	165.19	5.52	2.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	132	L	0.46	0.09	-0.41	1.13	1.00	1.06	131.17	5.52	3.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	133	G	0.47	0.11	0.10	1.13	1.04	1.03	75.07	5.52	-0.40
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	134	G	0.49	0.23	1.49	1.20	1.09	0.98	75.07	5.52	-0.40
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	135	G	0.51	0.46	4.23	1.32	1.12	0.95	75.07	5.52	-0.40
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	136	G	0.52	0.33	4.40	1.31	1.12	0.93	75.07	5.52	-0.40
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	137	Q	0.54	0.48	4.33	1.22	1.11	0.94	146.15	5.52	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	138	D	0.54	0.80	4.94	1.21	1.09	0.94	133.10	3.80	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	139	I	0.52	0.70	2.81	1.07	1.06	0.97	131.17	5.52	4.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	140	T	0.49	0.59	2.74	0.98	1.04	0.97	119.12	5.19	-0.70
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	141	D	0.49	0.35	1.29	0.93	1.01	0.95	133.10	3.80	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	142	F	0.48	0.86	0.71	0.86	0.98	0.97	165.19	5.52	2.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	143	T	0.47	0.52	0.54	0.88	0.95	0.96	119.12	5.19	-0.70
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	144	M	0.47	0.23	-0.73	0.81	0.93	1.03	149.21	5.28	1.90
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	145	Q	0.47	0.35	-1.23	0.81	0.93	1.05	146.15	5.52	-3.50
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	146	F	0.41	0.33	1.01	0.93	0.00	1.04	165.19	5.52	2.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	147	V	0.38	0.00	0.00	0.00	0.00	0.00	117.15	5.49	4.20
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	148	S	0.33	0.00	0.00	0.00	0.00	0.00	105.09	5.24	-0.80
5BVP_A Chain A of The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta	149	S	0.29	0.00	0.00	0.00	0.00	0.00	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	1	V	0.27	0.00	0.00	0.00	0.00	0.00	117.15	5.49	4.20
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	2	E	0.33	0.00	0.00	0.00	0.00	0.00	147.13	4.00	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	3	C	0.39	0.34	0.00	0.00	0.00	0.00	121.15	5.52	2.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	4	D	0.45	0.71	2.13	1.06	0.96	1.10	133.10	3.80	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	5	F	0.52	0.34	1.34	1.08	0.98	1.08	165.19	5.52	2.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	6	S	0.53	0.52	-1.09	1.05	1.00	1.13	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	7	P	0.54	0.42	-0.36	1.09	1.01	1.08	115.13	5.96	-1.60
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	8	L	0.54	0.48	-0.97	1.10	1.02	1.08	131.17	5.52	3.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	9	L	0.53	0.52	1.09	1.15	1.03	1.05	131.17	5.52	3.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	10	S	0.53	0.52	0.46	1.17	1.04	1.06	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	11	G	0.53	0.97	0.46	1.17	1.06	1.06	75.07	5.52	-0.40
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	12	T	0.52	2.03	2.63	1.22	1.07	1.03	119.12	5.19	-0.70
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	13	P	0.52	1.12	3.41	1.21	1.06	1.05	115.13	5.96	-1.60
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	14	P	0.51	1.78	2.21	1.17	1.03	1.07	115.13	5.96	-1.60
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	15	Q	0.50	1.98	2.40	1.17	1.00	1.05	146.15	5.52	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	16	V	0.50	1.11	0.34	1.12	0.97	1.08	117.15	5.49	4.20
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	17	Y	0.50	1.44	0.86	1.04	0.96	1.06	181.19	5.52	-1.30
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	18	N	0.51	1.62	1.16	0.96	0.96	1.03	132.12	5.52	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	19	F	0.51	1.80	-1.01	0.91	0.97	1.07	165.19	5.52	2.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	20	K	0.49	0.85	-1.01	0.91	0.99	1.07	146.19	8.75	-3.90
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	21	R	0.49	0.46	-2.06	0.83	0.99	1.06	174.20	9.75	-4.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	22	L	0.50	0.77	-2.31	0.74	0.98	1.08	131.17	5.52	3.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	23	V	0.50	0.62	0.00	0.88	0.97	1.03	117.15	5.49	4.20
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	24	F	0.52	0.17	-0.61	0.91	0.97	1.10	165.19	5.52	2.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	25	T	0.53	0.33	-0.21	0.99	0.97	1.09	119.12	5.19	-0.70
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	26	N	0.54	0.69	0.83	1.07	0.98	1.07	132.12	5.52	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	27	C	0.54	1.29	2.36	1.22	0.97	0.99	121.15	5.52	2.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	28	N	0.55	0.74	2.36	1.22	0.96	1.01	132.12	5.52	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	29	Y	0.57	0.66	2.36	1.22	0.96	1.01	181.19	5.52	-1.30
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	30	N	0.56	2.47	2.17	1.14	0.97	1.03	132.12	5.52	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	31	L	0.56	1.27	0.66	1.06	0.99	1.01	131.17	5.52	3.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	32	T	0.56	0.67	-1.66	0.92	1.00	1.08	119.12	5.19	-0.70
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	33	K	0.55	0.56	-0.46	0.96	1.00	1.05	146.19	8.75	-3.90
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	34	L	0.55	0.56	-2.77	0.82	0.99	1.12	131.17	5.52	3.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	35	L	0.55	0.33	-2.77	0.82	0.97	1.10	131.17	5.52	3.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	36	S	0.56	0.22	-2.59	0.89	0.95	1.11	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	37	L	0.57	0.20	-3.93	0.82	0.94	1.18	131.17	5.52	3.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	38	F	0.57	0.39	-1.61	0.96	0.94	1.11	165.19	5.52	2.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	39	S	0.58	0.49	1.13	1.08	0.96	1.06	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	40	V	0.58	0.51	-1.11	0.96	0.98	1.07	117.15	5.49	4.20
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	41	N	0.57	0.85	0.94	1.02	0.99	1.02	132.12	5.52	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	42	D	0.58	0.34	2.46	1.10	0.99	1.06	133.10	3.80	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	43	F	0.57	0.62	2.46	1.10	0.98	1.06	165.19	5.52	2.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	44	T	0.56	0.66	3.84	1.17	0.98	1.01	119.12	5.19	-0.70
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	45	C	0.57	0.28	1.70	1.01	0.99	1.07	121.15	5.52	2.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	46	S	0.55	0.43	1.20	1.01	1.00	1.09	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	47	Q	0.54	0.46	2.81	1.14	1.02	1.08	146.15	5.52	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	48	I	0.54	0.87	2.37	1.10	1.03	1.10	131.17	5.52	4.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	49	S	0.52	0.66	2.47	1.02	1.02	1.05	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	50	P	0.51	0.27	0.40	0.88	1.00	1.07	115.13	5.96	-1.60
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	51	A	0.51	0.38	-0.16	0.84	0.97	1.08	89.09	5.57	1.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	52	A	0.51	0.38	1.91	0.98	0.95	1.06	89.09	5.57	1.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	53	I	0.52	0.40	1.99	0.99	0.94	1.03	131.17	5.52	4.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	54	A	0.53	0.21	1.89	0.95	0.95	1.08	89.09	5.57	1.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	55	S	0.55	0.33	1.31	1.02	0.96	1.09	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	56	N	0.55	0.63	1.94	1.13	0.97	1.08	132.12	5.52	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	57	C	0.56	0.83	4.01	1.26	0.97	1.06	121.15	5.52	2.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	58	Y	0.57	0.51	2.40	1.25	0.98	1.09	181.19	5.52	-1.30
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	59	S	0.58	0.22	0.33	1.12	0.98	1.11	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	60	S	0.57	0.34	-1.99	0.98	0.98	1.18	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	61	L	0.56	0.37	-0.76	1.02	0.97	1.10	131.17	5.52	3.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	62	I	0.55	0.43	-0.76	1.02	0.95	1.10	131.17	5.52	4.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	63	L	0.54	0.28	-3.00	0.90	0.94	1.11	131.17	5.52	3.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	64	D	0.53	0.45	-3.00	0.90	0.93	1.11	133.10	3.80	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	65	Y	0.52	1.00	-1.96	0.98	0.93	1.10	181.19	5.52	-1.30
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	66	F	0.52	1.88	-0.51	1.13	0.93	1.09	165.19	5.52	2.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	67	S	0.53	0.93	-0.51	1.13	0.93	1.09	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	68	Y	0.54	0.80	-1.01	1.12	0.94	1.11	181.19	5.52	-1.30
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	69	P	0.55	0.91	-1.34	1.04	0.94	1.06	115.13	5.96	-1.60
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	70	L	0.56	1.36	0.79	1.10	0.95	1.04	131.17	5.52	3.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	71	S	0.57	1.16	0.79	1.10	0.97	1.04	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	72	M	0.58	1.25	2.49	1.15	1.01	0.99	149.21	5.28	1.90
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	73	K	0.59	1.25	0.87	1.02	1.04	1.02	146.19	8.75	-3.90
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	74	S	0.61	1.25	3.11	1.14	1.05	0.99	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	75	D	0.63	0.94	1.66	1.00	1.04	1.04	133.10	3.80	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	76	L	0.63	0.63	3.19	1.12	1.02	1.07	131.17	5.52	3.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	77	S	0.62	0.63	3.30	1.18	1.00	1.08	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	78	V	0.61	0.38	2.67	1.07	1.00	1.09	117.15	5.49	4.20
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	79	S	0.59	0.46	2.06	1.09	1.01	1.09	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	80	S	0.58	0.53	3.67	1.22	1.03	1.06	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	81	A	0.58	0.50	1.60	1.08	1.04	1.08	89.09	5.57	1.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	82	G	0.57	0.50	3.06	1.21	1.05	1.03	75.07	5.52	-0.40
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	83	P	0.56	0.64	2.99	1.15	1.05	1.03	115.13	5.96	-1.60
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	84	I	0.55	0.55	0.74	1.03	1.03	1.04	131.17	5.52	4.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	85	S	0.55	0.90	1.44	1.16	1.02	1.00	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	86	Q	0.56	0.91	0.36	1.10	1.00	1.04	146.15	5.52	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	87	F	0.57	2.59	0.87	1.03	0.98	1.02	165.19	5.52	2.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	88	N	0.58	3.35	2.87	1.10	0.99	1.00	132.12	5.52	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	89	Y	0.58	2.59	2.87	1.10	1.01	1.00	181.19	5.52	-1.30
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	90	K	0.58	2.59	0.70	1.05	1.03	1.01	146.19	8.75	-3.90
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	91	Q	0.58	2.16	2.94	1.16	1.05	1.00	146.15	5.52	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	92	S	0.57	2.22	2.94	1.16	1.05	1.00	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	93	F	0.57	1.71	3.51	1.22	1.04	0.99	165.19	5.52	2.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	94	S	0.57	1.43	3.44	1.21	1.05	0.98	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	95	N	0.56	0.57	2.79	1.24	1.04	1.04	132.12	5.52	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	96	P	0.54	0.54	0.54	1.12	1.03	1.07	115.13	5.96	-1.60
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	97	T	0.53	0.28	0.71	1.10	1.00	1.08	119.12	5.19	-0.70
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	98	C	0.52	0.15	-1.53	0.98	0.96	1.12	121.15	5.52	2.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	99	L	0.51	0.10	-2.23	0.85	0.93	1.16	131.17	5.52	3.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	100	I	0.50	0.10	-1.79	0.77	0.92	1.14	131.17	5.52	4.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	101	L	0.51	0.13	-3.06	0.71	0.92	1.20	131.17	5.52	3.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	102	A	0.51	0.25	-2.96	0.76	0.93	1.15	89.09	5.57	1.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	103	T	0.52	0.48	-1.34	0.81	0.94	1.13	119.12	5.19	-0.70
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	104	V	0.51	0.94	0.80	0.96	0.95	1.08	117.15	5.49	4.20
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	105	P	0.52	0.76	0.80	0.96	0.95	1.08	115.13	5.96	-1.60
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	106	H	0.53	0.76	1.24	1.01	0.96	1.06	155.16	6.74	-3.20
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	107	N	0.54	1.49	1.24	1.01	0.97	1.06	132.12	5.52	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	108	L	0.53	0.67	0.63	1.00	0.99	1.02	131.17	5.52	3.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	109	T	0.54	0.72	1.07	0.92	1.01	1.00	119.12	5.19	-0.70
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	110	T	0.53	0.89	1.59	0.93	1.03	0.98	119.12	5.19	-0.70
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	111	I	0.52	1.67	0.89	0.92	1.04	1.02	131.17	5.52	4.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	112	T	0.50	0.95	0.89	0.92	1.05	1.02	119.12	5.19	-0.70
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	113	K	0.51	1.32	0.96	0.93	1.05	1.02	146.19	8.75	-3.90
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	114	P	0.50	2.95	-0.06	0.96	1.04	1.06	115.13	5.96	-1.60
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	115	L	0.50	2.74	2.01	1.09	1.02	1.04	131.17	5.52	3.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	116	K	0.51	2.15	1.00	1.12	1.00	1.07	146.19	8.75	-3.90
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	117	Y	0.52	0.97	-0.96	1.04	0.97	1.10	181.19	5.52	-1.30
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	118	S	0.53	1.90	-0.26	1.05	0.95	1.06	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	119	Y	0.53	1.90	1.87	1.11	0.95	1.02	181.19	5.52	-1.30
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	120	I	0.53	0.65	1.26	1.13	0.96	1.09	131.17	5.52	4.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	121	N	0.55	0.65	2.46	1.18	0.98	1.06	132.12	5.52	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	122	K	0.55	0.81	2.13	1.11	1.00	1.05	146.19	8.75	-3.90
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	123	C	0.56	1.00	1.09	1.03	1.01	1.04	121.15	5.52	2.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	124	S	0.56	0.51	0.91	1.05	1.01	1.05	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	125	R	0.56	0.34	0.84	1.03	1.00	1.08	174.20	9.75	-4.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	126	F	0.56	1.07	1.46	1.09	0.99	1.07	165.19	5.52	2.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	127	L	0.56	1.34	2.69	1.13	1.00	1.00	131.17	5.52	3.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	128	S	0.56	1.34	2.36	1.06	1.01	0.98	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	129	D	0.56	2.23	2.50	1.06	1.02	0.98	133.10	3.80	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	130	D	0.54	4.68	4.93	1.08	1.04	0.95	133.10	3.80	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	131	R	0.53	2.59	5.71	1.07	1.04	0.97	174.20	9.75	-4.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	132	T	0.53	2.40	5.09	1.08	1.04	0.97	119.12	5.19	-0.70
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	133	E	0.53	2.49	4.51	1.02	1.04	0.99	147.13	4.00	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	134	V	0.53	1.05	1.77	0.89	1.03	1.05	117.15	5.49	4.20
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	135	P	0.53	0.54	0.64	0.83	1.02	1.12	115.13	5.96	-1.60
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	136	Q	0.53	0.50	0.90	0.91	1.00	1.10	146.15	5.52	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	137	L	0.55	0.68	0.09	0.90	0.99	1.13	131.17	5.52	3.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	138	V	0.57	0.71	1.61	1.05	0.98	1.05	117.15	5.49	4.20
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	139	N	0.59	0.71	2.17	0.98	0.98	1.04	132.12	5.52	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	140	A	0.61	1.35	1.04	1.00	0.99	1.06	89.09	5.57	1.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	141	N	0.60	2.43	3.29	1.12	1.00	1.03	132.12	5.52	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	142	Q	0.60	2.34	4.11	1.26	1.01	0.98	146.15	5.52	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	143	Y	0.60	1.24	3.31	1.21	1.01	1.07	181.19	5.52	-1.30
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	144	S	0.59	0.57	2.49	1.19	1.00	1.12	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	145	P	0.58	0.44	2.41	1.17	0.99	1.15	115.13	5.96	-1.60
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	146	C	0.55	0.20	0.41	1.10	0.96	1.17	121.15	5.52	2.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	147	V	0.52	0.11	0.16	1.01	0.94	1.20	117.15	5.49	4.20
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	148	S	0.51	0.11	-0.47	1.02	0.93	1.21	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	149	I	0.51	0.27	0.16	1.01	0.95	1.20	131.17	5.52	4.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	150	V	0.51	0.53	0.70	0.97	0.99	1.13	117.15	5.49	4.20
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	151	P	0.51	0.30	0.70	0.97	1.02	1.13	115.13	5.96	-1.60
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	152	S	0.51	0.44	-1.66	0.91	1.04	1.11	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	153	T	0.51	1.03	0.60	0.94	1.03	1.07	119.12	5.19	-0.70
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	154	V	0.51	1.12	2.56	1.08	1.01	1.00	117.15	5.49	4.20
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	155	W	0.52	0.83	3.07	1.09	1.00	0.97	204.23	5.52	-0.90
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	156	E	0.52	0.95	3.57	1.09	1.02	0.95	147.13	4.00	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	157	D	0.52	2.02	2.56	1.12	1.03	0.98	133.10	3.80	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	158	G	0.51	3.00	2.81	1.21	1.04	0.95	75.07	5.52	-0.40
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	159	D	0.52	3.40	4.84	1.21	1.04	0.95	133.10	3.80	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	160	Y	0.52	4.07	4.54	1.25	1.02	0.96	181.19	5.52	-1.30
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	161	Y	0.52	7.12	3.97	1.18	1.01	0.98	181.19	5.52	-1.30
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	162	R	0.53	3.52	1.84	1.04	1.01	1.04	174.20	9.75	-4.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	163	K	0.53	3.01	1.34	1.03	1.02	1.06	146.19	8.75	-3.90
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	164	Q	0.53	2.97	1.91	1.09	1.03	1.04	146.15	5.52	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	165	L	0.55	1.25	0.87	1.01	1.03	1.06	131.17	5.52	3.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	166	S	0.55	1.08	1.39	0.98	1.03	1.05	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	167	P	0.56	0.62	1.39	1.06	1.04	1.05	115.13	5.96	-1.60
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	168	L	0.55	0.74	1.34	1.14	1.04	1.02	131.17	5.52	3.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	169	E	0.54	0.55	3.47	1.28	1.06	0.97	147.13	4.00	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	170	G	0.54	0.37	1.11	1.21	1.07	0.95	75.07	5.52	-0.40
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	171	G	0.54	0.37	-0.50	1.08	1.06	0.98	75.07	5.52	-0.40
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	172	G	0.54	0.16	0.29	1.07	1.03	1.00	75.07	5.52	-0.40
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	173	W	0.56	0.16	-0.53	1.06	0.98	1.03	204.23	5.52	-0.90
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	174	L	0.56	0.22	-0.41	1.04	0.96	1.05	131.17	5.52	3.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	175	V	0.58	0.22	-0.41	1.04	0.96	1.05	117.15	5.49	4.20
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	176	A	0.58	0.28	-0.30	1.02	0.99	1.07	89.09	5.57	1.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	177	S	0.59	0.49	1.87	1.02	1.04	1.07	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	178	G	0.60	0.49	2.66	1.01	1.07	1.09	75.07	5.52	-0.40
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	179	S	0.61	0.49	3.49	1.03	1.07	1.05	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	180	T	0.62	0.36	2.59	1.02	1.03	1.01	119.12	5.19	-0.70
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	181	V	0.63	0.53	2.40	0.95	0.99	1.00	117.15	5.49	4.20
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	182	A	0.63	0.69	2.70	0.84	0.96	0.99	89.09	5.57	1.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	183	M	0.63	0.82	2.63	0.77	0.96	0.99	149.21	5.28	1.90
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	184	T	0.62	0.91	0.57	0.72	0.99	1.04	119.12	5.19	-0.70
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	185	E	0.63	1.57	1.96	0.79	1.00	0.99	147.13	4.00	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	186	Q	0.62	1.57	1.06	0.78	1.00	0.96	146.15	5.52	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	187	L	0.61	1.07	2.47	0.92	0.98	0.96	131.17	5.52	3.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	188	Q	0.59	0.54	0.41	0.86	0.95	0.99	146.15	5.52	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	189	M	0.57	0.31	0.11	0.98	0.93	0.99	149.21	5.28	1.90
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	190	G	0.56	0.26	-1.89	0.91	0.93	1.01	75.07	5.52	-0.40
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	191	F	0.55	0.22	0.17	0.96	0.94	0.96	165.19	5.52	2.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	192	G	0.55	0.16	-1.21	0.89	0.95	1.02	75.07	5.52	-0.40
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	193	I	0.55	0.29	0.24	0.95	0.95	1.04	131.17	5.52	4.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	194	T	0.54	0.52	-0.84	0.89	0.95	1.08	119.12	5.19	-0.70
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	195	V	0.55	0.52	1.29	1.02	0.95	1.05	117.15	5.49	4.20
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	196	Q	0.56	1.06	1.21	0.94	0.96	1.06	146.15	5.52	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	197	Y	0.57	1.06	3.10	1.01	0.98	1.02	181.19	5.52	-1.30
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	198	G	0.59	2.30	3.36	1.09	1.02	1.00	75.07	5.52	-0.40
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	199	T	0.59	1.78	4.81	1.23	1.05	0.95	119.12	5.19	-0.70
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	200	T	0.58	0.84	3.43	1.16	1.06	1.00	119.12	5.19	-0.70
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	201	N	0.57	0.46	3.90	1.17	1.05	1.04	132.12	5.52	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	202	S	0.57	0.49	3.39	1.16	1.02	1.07	105.09	5.24	-0.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	203	V	0.56	0.68	3.46	1.17	1.00	1.07	117.15	5.49	4.20
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	204	C	0.57	0.35	1.40	1.11	0.99	1.12	121.15	5.52	2.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	205	P	0.56	0.45	1.51	1.00	1.00	1.13	115.13	5.96	-1.60
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	206	K	0.56	0.52	-0.73	0.88	1.00	1.14	146.19	8.75	-3.90
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	207	L	0.50	0.99	0.10	0.90	0.00	1.09	131.17	5.52	3.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	208	E	0.44	0.00	0.00	0.00	0.00	0.00	147.13	4.00	-3.50
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	209	F	0.38	0.00	0.00	0.00	0.00	0.00	165.19	5.52	2.80
4XAK_A Chain A of Crystal structure of potent neutralizing antibody m336 in complex with MERS Co-V RBD	210	A	0.32	0.00	0.00	0.00	0.00	0.00	89.09	5.57	1.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	1	R	0.18	0.00	0.00	0.00	0.00	0.00	174.20	9.75	-4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	2	S	0.22	0.00	0.00	0.00	0.00	0.00	105.09	5.24	-0.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	3	T	0.27	1.31	0.00	0.00	0.00	0.00	119.12	5.19	-0.70
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	4	T	0.29	0.67	0.69	0.88	1.03	1.04	119.12	5.19	-0.70
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	5	L	0.32	0.42	-1.23	0.83	0.99	1.09	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	6	L	0.31	0.24	-3.47	0.71	0.95	1.13	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	7	A	0.31	0.17	-3.91	0.66	0.93	1.15	89.09	5.57	1.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	8	L	0.30	0.17	-5.97	0.61	0.91	1.20	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	9	L	0.29	0.15	-5.19	0.60	0.91	1.22	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	10	A	0.28	0.12	-5.19	0.60	0.91	1.22	89.09	5.57	1.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	11	L	0.27	0.12	-6.80	0.59	0.91	1.24	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	12	V	0.25	0.23	-5.76	0.67	0.91	1.23	117.15	5.49	4.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	13	L	0.25	0.19	-5.76	0.67	0.91	1.23	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	14	L	0.27	0.17	-6.59	0.64	0.90	1.28	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	15	Y	0.28	0.31	-4.34	0.76	0.91	1.24	181.19	5.52	-1.30
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	16	L	0.29	0.37	-3.00	0.91	0.93	1.17	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	17	V	0.31	0.45	-1.39	0.92	0.95	1.14	117.15	5.49	4.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	18	S	0.32	0.24	-1.39	0.92	0.97	1.14	105.09	5.24	-0.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	19	G	0.31	0.21	-1.64	0.83	0.98	1.17	75.07	5.52	-0.40
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	20	A	0.33	0.25	-1.64	0.83	0.96	1.15	89.09	5.57	1.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	21	L	0.35	0.37	-0.51	0.90	0.94	1.08	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	22	V	0.36	0.37	-1.14	0.79	0.93	1.09	117.15	5.49	4.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	23	F	0.37	0.30	-3.27	0.65	0.92	1.14	165.19	5.52	2.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	24	R	0.40	0.64	-2.46	0.66	0.93	1.11	174.20	9.75	-4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	25	A	0.43	1.49	-0.29	0.72	0.96	1.08	89.09	5.57	1.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	26	L	0.44	2.66	0.54	0.86	0.99	1.03	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	27	E	0.46	1.85	2.16	0.91	1.03	1.03	147.13	4.00	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	28	Q	0.51	3.17	2.67	0.88	1.06	1.03	146.15	5.52	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	29	P	0.52	6.66	3.23	0.93	1.07	1.02	115.13	5.96	-1.60
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	30	H	0.53	6.66	5.40	0.98	1.06	0.99	155.16	6.74	-3.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	31	E	0.57	3.88	4.59	0.97	1.06	1.02	147.13	4.00	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	32	Q	0.59	4.35	4.59	0.97	1.06	1.02	146.15	5.52	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	33	Q	0.59	6.26	4.89	0.89	1.05	0.99	146.15	5.52	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	34	A	0.57	6.26	5.70	0.86	1.05	0.95	89.09	5.57	1.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	35	Q	0.57	2.98	3.27	0.84	1.04	1.01	146.15	5.52	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	36	R	0.57	1.70	3.23	0.92	1.03	0.99	174.20	9.75	-4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	37	E	0.57	2.92	3.49	0.89	1.02	0.97	147.13	4.00	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	38	L	0.57	1.25	2.66	0.87	1.02	1.01	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	39	G	0.58	1.25	2.40	0.86	1.02	0.99	75.07	5.52	-0.40
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	40	E	0.57	1.25	2.91	0.83	1.02	0.99	147.13	4.00	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	41	V	0.54	3.04	2.61	0.87	1.03	1.00	117.15	5.49	4.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	42	R	0.53	2.66	2.61	0.87	1.03	0.98	174.20	9.75	-4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	43	E	0.55	1.27	0.49	0.73	1.03	1.03	147.13	4.00	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	44	K	0.55	3.34	-0.03	0.76	1.01	1.04	146.19	8.75	-3.90
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	45	F	0.55	1.72	0.80	0.79	0.98	0.99	165.19	5.52	2.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	46	L	0.54	1.35	0.50	0.79	0.96	1.02	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	47	R	0.54	1.05	-0.31	0.90	0.94	1.05	174.20	9.75	-4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	48	A	0.54	0.65	-0.93	0.92	0.93	1.12	89.09	5.57	1.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	49	H	0.54	0.58	-0.14	0.91	0.93	1.16	155.16	6.74	-3.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	50	P	0.57	0.40	2.10	1.03	0.93	1.13	115.13	5.96	-1.60
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	51	C	0.57	0.66	2.93	1.10	0.94	1.13	121.15	5.52	2.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	52	V	0.58	0.84	3.49	1.15	0.97	1.12	117.15	5.49	4.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	53	S	0.58	0.94	4.30	1.12	1.01	1.09	105.09	5.24	-0.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	54	D	0.58	1.45	2.69	0.98	1.03	1.11	133.10	3.80	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	55	Q	0.58	1.93	3.30	1.04	1.05	1.04	146.15	5.52	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	56	E	0.55	1.19	2.51	1.05	1.03	1.02	147.13	4.00	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	57	L	0.53	0.59	0.27	0.93	1.00	1.05	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	58	G	0.53	0.24	-2.30	0.79	0.97	1.09	75.07	5.52	-0.40
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	59	L	0.51	0.27	-2.34	0.79	0.95	1.08	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	60	L	0.47	0.57	-2.34	0.79	0.95	1.08	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	61	I	0.44	0.43	-1.56	0.78	0.96	1.10	131.17	5.52	4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	62	K	0.44	0.53	-2.07	0.65	0.98	1.13	146.19	8.75	-3.90
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	63	E	0.43	1.07	0.67	0.78	0.98	1.07	147.13	4.00	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	64	V	0.42	1.54	2.29	0.79	0.97	1.04	117.15	5.49	4.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	65	A	0.44	0.64	2.11	0.80	0.96	1.06	89.09	5.57	1.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	66	D	0.46	0.36	2.11	0.88	0.95	1.05	133.10	3.80	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	67	A	0.46	0.48	1.81	1.00	0.97	1.05	89.09	5.57	1.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	68	L	0.47	0.47	3.16	1.15	1.00	0.98	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	69	G	0.51	0.29	3.16	1.15	1.03	0.98	75.07	5.52	-0.40
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	70	G	0.53	0.47	3.16	1.15	1.05	0.98	75.07	5.52	-0.40
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	71	G	0.55	0.89	3.16	1.27	1.06	0.98	75.07	5.52	-0.40
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	72	A	0.59	1.56	5.59	1.29	1.07	0.92	89.09	5.57	1.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	73	D	0.62	2.27	5.51	1.21	1.07	0.93	133.10	3.80	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	74	P	0.63	3.07	5.63	1.19	1.07	0.95	115.13	5.96	-1.60
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	75	E	0.65	4.14	5.11	1.10	1.07	0.98	147.13	4.00	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	76	T	0.65	3.32	5.74	1.21	1.05	0.97	119.12	5.19	-0.70
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	77	S	0.65	2.17	4.61	1.10	1.02	1.00	105.09	5.24	-0.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	78	H	0.65	1.32	2.89	1.02	0.99	0.98	155.16	6.74	-3.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	79	S	0.63	1.53	3.20	1.12	0.96	0.98	105.09	5.24	-0.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	80	A	0.61	0.94	1.14	1.07	0.95	1.03	89.09	5.57	1.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	81	W	0.58	0.68	1.03	1.09	0.94	1.01	204.23	5.52	-0.90
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	82	D	0.54	0.68	1.66	1.16	0.96	1.00	133.10	3.80	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	83	L	0.52	0.68	1.03	1.05	0.98	1.00	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	84	G	0.49	0.56	-0.59	1.04	0.99	1.01	75.07	5.52	-0.40
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	85	S	0.46	0.29	-0.47	0.99	0.99	1.04	105.09	5.24	-0.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	86	A	0.42	0.31	-3.21	0.86	0.97	1.07	89.09	5.57	1.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	87	F	0.40	0.41	-0.97	0.98	0.95	1.03	165.19	5.52	2.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	88	F	0.38	0.31	-0.97	0.98	0.96	1.03	165.19	5.52	2.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	89	F	0.35	0.44	-1.16	0.92	0.98	1.02	165.19	5.52	2.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	90	S	0.34	0.35	-2.60	0.89	1.01	1.03	105.09	5.24	-0.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	91	G	0.34	0.29	-2.43	0.87	1.02	1.04	75.07	5.52	-0.40
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	92	T	0.35	0.48	-0.37	0.92	1.01	1.01	119.12	5.19	-0.70
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	93	I	0.37	0.51	1.69	0.97	0.99	0.99	131.17	5.52	4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	94	I	0.39	0.36	-0.39	0.84	0.98	1.01	131.17	5.52	4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	95	T	0.44	0.25	-0.39	0.84	0.99	1.01	119.12	5.19	-0.70
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	96	T	0.48	0.56	-1.40	0.86	0.99	1.04	119.12	5.19	-0.70
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	97	I	0.50	0.79	0.56	1.02	0.99	1.00	131.17	5.52	4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	98	G	0.53	0.88	2.70	1.17	0.99	0.95	75.07	5.52	-0.40
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	99	Y	0.56	0.45	1.43	1.11	0.98	1.02	181.19	5.52	-1.30
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	100	G	0.57	0.65	0.99	1.06	0.98	1.04	75.07	5.52	-0.40
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	101	N	0.60	0.54	0.81	1.08	0.97	1.05	132.12	5.52	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	102	V	0.58	0.68	0.60	0.99	0.96	1.05	117.15	5.49	4.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	103	A	0.58	0.99	1.61	0.97	0.96	1.02	89.09	5.57	1.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	104	L	0.57	1.03	2.23	0.95	0.98	1.02	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	105	R	0.55	1.40	1.53	0.83	1.01	1.06	174.20	9.75	-4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	106	T	0.54	1.37	2.87	0.98	1.04	0.99	119.12	5.19	-0.70
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	107	D	0.52	3.25	3.17	1.02	1.05	0.96	133.10	3.80	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	108	A	0.49	1.37	3.17	1.02	1.05	0.96	89.09	5.57	1.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	109	G	0.47	0.82	1.26	0.97	1.03	0.99	75.07	5.52	-0.40
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	110	R	0.42	0.26	0.71	1.00	1.00	1.06	174.20	9.75	-4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	111	L	0.39	0.18	-1.86	0.86	0.97	1.10	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	112	F	0.36	0.16	-3.47	0.85	0.94	1.11	165.19	5.52	2.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	113	C	0.32	0.13	-4.56	0.79	0.92	1.15	121.15	5.52	2.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	114	I	0.30	0.16	-4.86	0.75	0.90	1.17	131.17	5.52	4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	115	F	0.28	0.15	-4.86	0.75	0.89	1.17	165.19	5.52	2.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	116	Y	0.26	0.21	-4.07	0.74	0.89	1.22	181.19	5.52	-1.30
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	117	A	0.26	0.29	-3.46	0.79	0.89	1.14	89.09	5.57	1.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	118	L	0.27	0.24	-3.46	0.79	0.91	1.14	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	119	V	0.28	0.23	-1.84	0.92	0.92	1.14	117.15	5.49	4.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	120	G	0.29	0.19	-2.89	0.84	0.94	1.15	75.07	5.52	-0.40
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	121	I	0.29	0.20	-4.50	0.83	0.95	1.15	131.17	5.52	4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	122	P	0.31	0.27	-2.37	0.97	0.95	1.10	115.13	5.96	-1.60
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	123	L	0.32	0.19	-2.99	0.97	0.94	1.07	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	124	F	0.32	0.22	-5.11	0.83	0.93	1.12	165.19	5.52	2.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	125	G	0.33	0.12	-5.29	0.85	0.92	1.13	75.07	5.52	-0.40
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	126	I	0.34	0.15	-5.29	0.72	0.92	1.13	131.17	5.52	4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	127	L	0.35	0.17	-3.16	0.86	0.92	1.08	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	128	L	0.37	0.12	-2.37	0.85	0.93	1.12	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	129	A	0.39	0.18	-2.37	0.85	0.94	1.12	89.09	5.57	1.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	130	G	0.43	0.36	0.20	0.99	0.96	1.08	75.07	5.52	-0.40
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	131	V	0.44	0.85	2.11	1.04	0.98	1.03	117.15	5.49	4.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	132	G	0.46	0.69	2.11	1.04	1.00	1.03	75.07	5.52	-0.40
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	133	D	0.47	0.69	2.63	1.17	1.01	1.00	133.10	3.80	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	134	R	0.48	1.25	2.74	1.15	1.03	1.02	174.20	9.75	-4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	135	L	0.49	1.69	4.20	1.28	1.04	0.97	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	136	G	0.50	0.83	2.07	1.14	1.05	1.02	75.07	5.52	-0.40
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	137	S	0.51	0.83	1.24	1.07	1.05	1.02	105.09	5.24	-0.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	138	S	0.50	1.37	0.94	1.07	1.03	1.05	105.09	5.24	-0.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	139	L	0.50	1.37	3.07	1.21	1.00	1.00	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	140	R	0.49	0.72	1.11	1.05	0.97	1.04	174.20	9.75	-4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	141	H	0.50	0.53	1.00	1.07	0.96	1.02	155.16	6.74	-3.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	142	G	0.51	0.88	0.37	1.00	0.95	1.03	75.07	5.52	-0.40
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	143	I	0.52	0.31	0.54	0.99	0.95	1.02	131.17	5.52	4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	144	G	0.53	0.40	1.06	0.96	0.94	1.02	75.07	5.52	-0.40
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	145	H	0.53	0.41	1.06	0.92	0.94	1.01	155.16	6.74	-3.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	146	I	0.53	0.41	-0.90	0.76	0.93	1.05	131.17	5.52	4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	147	E	0.54	0.36	-1.07	0.78	0.92	1.04	147.13	4.00	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	148	A	0.55	0.22	-3.20	0.64	0.92	1.10	89.09	5.57	1.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	149	I	0.57	0.62	-2.69	0.65	0.93	1.07	131.17	5.52	4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	150	F	0.59	0.37	-2.97	0.72	0.94	1.03	165.19	5.52	2.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	151	L	0.60	0.50	-3.79	0.75	0.95	1.07	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	152	K	0.61	0.53	-4.61	0.73	0.95	1.11	146.19	8.75	-3.90
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	153	W	0.62	0.95	-3.17	0.88	0.96	1.10	204.23	5.52	-0.90
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	154	H	0.63	1.79	-1.56	1.01	0.96	1.10	155.16	6.74	-3.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	155	V	0.64	1.55	0.87	1.03	0.98	1.04	117.15	5.49	4.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	156	P	0.65	1.21	-1.26	0.97	1.00	1.09	115.13	5.96	-1.60
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	157	P	0.66	0.66	-0.36	0.90	1.01	1.16	115.13	5.96	-1.60
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	158	E	0.65	1.75	-0.06	0.90	1.00	1.12	147.13	4.00	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	159	L	0.64	0.84	-0.06	0.90	0.98	1.12	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	160	V	0.64	0.45	-1.67	0.77	0.95	1.15	117.15	5.49	4.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	161	R	0.63	0.35	-1.04	0.76	0.94	1.14	174.20	9.75	-4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	162	V	0.63	0.42	-1.86	0.75	0.93	1.17	117.15	5.49	4.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	163	L	0.62	0.57	-1.14	0.75	0.93	1.11	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	164	S	0.61	0.24	-1.93	0.76	0.92	1.09	105.09	5.24	-0.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	165	A	0.60	0.28	-3.84	0.71	0.91	1.13	89.09	5.57	1.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	166	M	0.57	0.28	-4.63	0.72	0.90	1.11	149.21	5.28	1.90
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	167	L	0.56	0.17	-4.63	0.72	0.90	1.11	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	168	F	0.53	0.12	-6.70	0.59	0.90	1.13	165.19	5.52	2.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	169	L	0.49	0.12	-6.19	0.71	0.91	1.10	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	170	L	0.47	0.08	-5.39	0.80	0.91	1.18	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	171	I	0.43	0.07	-5.39	0.80	0.91	1.18	131.17	5.52	4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	172	G	0.40	0.07	-5.39	0.80	0.91	1.21	75.07	5.52	-0.40
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	173	C	0.36	0.08	-5.39	0.80	0.91	1.18	121.15	5.52	2.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	174	L	0.31	0.08	-4.60	0.79	0.91	1.20	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	175	L	0.28	0.07	-4.77	0.80	0.92	1.22	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	176	F	0.26	0.18	-4.84	0.72	0.93	1.22	165.19	5.52	2.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	177	V	0.26	0.34	-4.74	0.76	0.95	1.17	117.15	5.49	4.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	178	L	0.26	0.60	-2.69	0.82	0.98	1.12	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	179	T	0.26	0.60	-2.69	0.82	1.00	1.10	119.12	5.19	-0.70
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	180	P	0.26	0.60	-1.90	0.80	1.01	1.14	115.13	5.96	-1.60
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	181	T	0.27	0.63	-2.69	0.82	0.99	1.10	119.12	5.19	-0.70
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	182	F	0.30	0.23	-1.17	0.90	0.97	1.12	165.19	5.52	2.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	183	V	0.34	0.24	-2.19	0.93	0.94	1.16	117.15	5.49	4.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	184	F	0.38	0.16	-3.09	0.80	0.91	1.12	165.19	5.52	2.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	185	C	0.42	0.33	-2.71	0.77	0.90	1.12	121.15	5.52	2.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	186	Y	0.45	0.73	0.03	0.89	0.91	1.08	181.19	5.52	-1.30
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	187	M	0.48	0.89	-0.87	0.96	0.93	1.01	149.21	5.28	1.90
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	188	E	0.51	2.22	1.37	1.07	0.97	1.00	147.13	4.00	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	189	D	0.53	2.84	1.99	1.05	1.00	0.93	133.10	3.80	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	190	W	0.54	2.36	0.94	0.97	1.01	0.95	204.23	5.52	-0.90
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	191	S	0.53	2.36	2.66	0.99	1.02	0.95	105.09	5.24	-0.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	192	K	0.52	1.43	1.84	0.98	1.01	0.98	146.19	8.75	-3.90
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	193	L	0.47	0.95	-0.73	0.84	0.98	1.02	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	194	E	0.43	1.12	0.43	0.86	0.95	1.06	147.13	4.00	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	195	A	0.39	0.48	-1.81	0.74	0.93	1.07	89.09	5.57	1.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	196	I	0.35	0.43	-3.16	0.67	0.90	1.14	131.17	5.52	4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	197	Y	0.32	0.19	-2.37	0.66	0.89	1.15	181.19	5.52	-1.30
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	198	F	0.29	0.27	-2.74	0.69	0.90	1.16	165.19	5.52	2.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	199	V	0.26	0.31	-4.36	0.68	0.91	1.19	117.15	5.49	4.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	200	V	0.25	0.29	-2.47	0.75	0.93	1.16	117.15	5.49	4.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	201	T	0.24	0.48	-1.46	0.72	0.96	1.12	119.12	5.19	-0.70
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	202	L	0.26	0.48	-0.67	0.71	0.98	1.16	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	203	T	0.28	0.64	0.67	0.86	1.00	1.09	119.12	5.19	-0.70
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	204	T	0.32	0.38	-0.11	0.88	1.00	1.05	119.12	5.19	-0.70
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	205	V	0.35	0.46	-0.04	0.96	0.99	1.04	117.15	5.49	4.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	206	G	0.37	0.53	2.70	1.09	0.98	0.99	75.07	5.52	-0.40
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	207	F	0.40	0.58	1.69	1.11	0.98	1.02	165.19	5.52	2.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	208	G	0.43	0.58	0.41	1.05	0.99	1.09	75.07	5.52	-0.40
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	209	D	0.46	0.59	1.24	1.07	0.99	1.04	133.10	3.80	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	210	Y	0.49	0.68	1.24	1.07	0.97	1.04	181.19	5.52	-1.30
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	211	V	0.51	0.69	2.86	1.08	0.96	1.04	117.15	5.49	4.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	212	A	0.54	0.69	3.47	1.06	0.96	1.04	89.09	5.57	1.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	213	G	0.56	0.68	2.34	1.07	0.98	1.07	75.07	5.52	-0.40
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	214	A	0.58	1.80	3.21	1.04	1.01	1.03	89.09	5.57	1.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	215	D	0.59	3.08	4.60	1.11	1.04	0.97	133.10	3.80	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	216	P	0.60	5.20	5.73	1.23	1.06	0.95	115.13	5.96	-1.60
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	217	R	0.62	6.90	5.84	1.21	1.08	0.97	174.20	9.75	-4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	218	Q	0.64	6.39	5.84	1.33	1.09	0.97	146.15	5.52	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	219	D	0.64	4.17	4.71	1.22	1.09	0.99	133.10	3.80	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	220	S	0.63	3.34	4.14	1.16	1.08	1.01	105.09	5.24	-0.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	221	P	0.61	3.34	4.40	1.17	1.05	1.03	115.13	5.96	-1.60
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	222	A	0.58	3.09	3.84	1.24	1.02	1.04	89.09	5.57	1.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	223	Y	0.55	1.90	1.10	1.12	1.01	1.09	181.19	5.52	-1.30
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	224	Q	0.52	0.91	-0.36	0.99	1.00	1.14	146.15	5.52	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	225	P	0.49	0.95	-2.09	0.91	0.98	1.12	115.13	5.96	-1.60
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	226	L	0.45	0.53	-3.70	0.90	0.96	1.12	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	227	V	0.40	0.32	-4.86	0.87	0.92	1.08	117.15	5.49	4.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	228	W	0.37	0.14	-6.86	0.80	0.89	1.10	204.23	5.52	-0.90
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	229	F	0.33	0.14	-8.47	0.67	0.87	1.13	165.19	5.52	2.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	230	W	0.30	0.16	-8.47	0.67	0.87	1.13	204.23	5.52	-0.90
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	231	I	0.28	0.15	-7.13	0.82	0.88	1.06	131.17	5.52	4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	232	L	0.28	0.14	-7.01	0.77	0.91	1.11	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	233	L	0.29	0.14	-5.40	0.77	0.92	1.10	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	234	G	0.28	0.31	-4.24	0.80	0.92	1.14	75.07	5.52	-0.40
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	235	L	0.27	0.32	-4.41	0.82	0.92	1.13	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	236	A	0.29	0.40	-2.80	0.83	0.91	1.11	89.09	5.57	1.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	237	Y	0.29	0.54	-0.56	0.95	0.90	1.07	181.19	5.52	-1.30
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	238	F	0.32	0.48	-1.90	0.80	0.91	1.15	165.19	5.52	2.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	239	A	0.34	0.40	-1.90	0.80	0.92	1.15	89.09	5.57	1.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	240	S	0.37	0.36	-1.46	0.84	0.93	1.12	105.09	5.24	-0.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	241	V	0.36	0.61	-0.44	0.81	0.96	1.09	117.15	5.49	4.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	242	L	0.35	0.42	-0.27	0.80	0.98	1.10	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	243	T	0.37	0.31	0.24	0.92	1.00	1.07	119.12	5.19	-0.70
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	244	T	0.41	0.67	0.31	0.94	1.02	1.04	119.12	5.19	-0.70
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	245	I	0.40	0.86	-0.59	1.01	1.02	0.97	131.17	5.52	4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	246	G	0.43	0.49	-0.59	1.01	1.01	0.97	75.07	5.52	-0.40
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	247	N	0.44	0.67	-0.73	1.01	0.99	0.96	132.12	5.52	-3.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	248	W	0.43	0.71	-2.00	0.94	0.96	1.03	204.23	5.52	-0.90
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	249	L	0.37	0.53	-1.39	0.95	0.00	1.06	131.17	5.52	3.80
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	250	R	0.34	0.00	0.00	0.00	0.00	0.00	174.20	9.75	-4.50
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	251	V	0.30	0.00	0.00	0.00	0.00	0.00	117.15	5.49	4.20
4WFF_A Chain A of Human TRAAK K+ channel in a K+ bound nonconductive conformation	252	V	0.24	0.00	0.00	0.00	0.00	0.00	117.15	5.49	4.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	1	R	0.19	0.00	0.00	0.00	0.00	0.00	174.20	9.75	-4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	2	S	0.23	0.00	0.00	0.00	0.00	0.00	105.09	5.24	-0.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	3	T	0.27	1.27	0.00	0.00	0.00	0.00	119.12	5.19	-0.70
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	4	T	0.30	0.66	0.69	0.88	1.03	1.04	119.12	5.19	-0.70
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	5	L	0.32	0.40	-1.23	0.83	0.99	1.09	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	6	L	0.32	0.23	-3.47	0.71	0.95	1.13	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	7	A	0.31	0.16	-3.91	0.66	0.93	1.15	89.09	5.57	1.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	8	L	0.30	0.16	-5.97	0.61	0.91	1.20	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	9	L	0.29	0.15	-5.19	0.60	0.91	1.22	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	10	A	0.29	0.12	-5.19	0.60	0.91	1.22	89.09	5.57	1.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	11	L	0.28	0.12	-6.80	0.59	0.91	1.24	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	12	V	0.26	0.23	-5.76	0.67	0.91	1.23	117.15	5.49	4.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	13	L	0.25	0.18	-5.76	0.67	0.91	1.23	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	14	L	0.27	0.17	-6.59	0.64	0.90	1.28	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	15	Y	0.28	0.30	-4.34	0.76	0.91	1.24	181.19	5.52	-1.30
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	16	L	0.30	0.36	-3.00	0.91	0.93	1.17	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	17	V	0.32	0.44	-1.39	0.92	0.95	1.14	117.15	5.49	4.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	18	S	0.33	0.23	-1.39	0.92	0.97	1.14	105.09	5.24	-0.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	19	G	0.31	0.21	-1.64	0.83	0.98	1.17	75.07	5.52	-0.40
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	20	A	0.33	0.24	-1.64	0.83	0.96	1.15	89.09	5.57	1.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	21	L	0.36	0.36	-0.51	0.90	0.94	1.08	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	22	V	0.37	0.36	-1.14	0.79	0.93	1.09	117.15	5.49	4.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	23	F	0.38	0.30	-3.27	0.65	0.92	1.14	165.19	5.52	2.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	24	R	0.41	0.62	-2.46	0.66	0.93	1.11	174.20	9.75	-4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	25	A	0.44	1.45	-0.29	0.72	0.96	1.08	89.09	5.57	1.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	26	L	0.46	2.59	0.54	0.86	0.99	1.03	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	27	E	0.48	1.80	2.16	0.91	1.03	1.03	147.13	4.00	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	28	Q	0.53	3.09	2.67	0.88	1.06	1.03	146.15	5.52	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	29	P	0.54	6.48	3.23	0.93	1.07	1.02	115.13	5.96	-1.60
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	30	H	0.55	6.48	5.40	0.98	1.06	0.99	155.16	6.74	-3.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	31	E	0.59	3.78	4.59	0.97	1.06	1.02	147.13	4.00	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	32	Q	0.61	4.23	4.59	0.97	1.06	1.02	146.15	5.52	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	33	Q	0.61	6.09	4.89	0.89	1.05	0.99	146.15	5.52	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	34	A	0.59	6.09	5.70	0.86	1.05	0.95	89.09	5.57	1.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	35	Q	0.58	2.90	3.27	0.84	1.04	1.01	146.15	5.52	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	36	R	0.58	1.66	3.23	0.92	1.03	0.99	174.20	9.75	-4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	37	E	0.58	2.84	3.49	0.89	1.02	0.97	147.13	4.00	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	38	L	0.57	1.22	2.66	0.87	1.02	1.01	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	39	G	0.58	1.22	2.40	0.86	1.02	0.99	75.07	5.52	-0.40
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	40	E	0.58	1.22	2.91	0.83	1.02	0.99	147.13	4.00	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	41	V	0.55	2.95	2.61	0.87	1.03	1.00	117.15	5.49	4.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	42	R	0.53	2.58	2.61	0.87	1.03	0.98	174.20	9.75	-4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	43	E	0.55	1.23	0.49	0.73	1.03	1.03	147.13	4.00	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	44	K	0.55	3.25	-0.03	0.76	1.01	1.04	146.19	8.75	-3.90
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	45	F	0.55	1.68	0.80	0.79	0.98	0.99	165.19	5.52	2.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	46	L	0.54	1.32	0.50	0.79	0.96	1.02	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	47	R	0.54	1.02	-0.31	0.90	0.94	1.05	174.20	9.75	-4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	48	A	0.53	0.63	-0.93	0.92	0.93	1.12	89.09	5.57	1.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	49	H	0.53	0.57	-0.14	0.91	0.93	1.16	155.16	6.74	-3.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	50	P	0.56	0.39	2.10	1.03	0.93	1.13	115.13	5.96	-1.60
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	51	C	0.57	0.64	2.93	1.10	0.94	1.13	121.15	5.52	2.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	52	V	0.58	0.82	3.49	1.15	0.97	1.12	117.15	5.49	4.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	53	S	0.57	0.91	4.30	1.12	1.01	1.09	105.09	5.24	-0.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	54	D	0.58	1.41	2.69	0.98	1.03	1.11	133.10	3.80	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	55	Q	0.58	1.88	3.30	1.04	1.05	1.04	146.15	5.52	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	56	E	0.55	1.15	2.51	1.05	1.03	1.02	147.13	4.00	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	57	L	0.52	0.57	0.27	0.93	1.00	1.05	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	58	G	0.51	0.23	-2.30	0.79	0.97	1.09	75.07	5.52	-0.40
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	59	L	0.49	0.27	-2.34	0.79	0.95	1.08	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	60	L	0.46	0.56	-2.34	0.79	0.95	1.08	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	61	I	0.43	0.42	-1.56	0.78	0.96	1.10	131.17	5.52	4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	62	K	0.42	0.51	-2.07	0.65	0.98	1.13	146.19	8.75	-3.90
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	63	E	0.41	1.04	0.67	0.78	0.98	1.07	147.13	4.00	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	64	V	0.39	1.50	2.29	0.79	0.97	1.04	117.15	5.49	4.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	65	A	0.42	0.62	2.11	0.80	0.96	1.06	89.09	5.57	1.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	66	D	0.44	0.35	2.11	0.88	0.95	1.05	133.10	3.80	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	67	A	0.44	0.47	1.81	1.00	0.97	1.05	89.09	5.57	1.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	68	L	0.44	0.46	3.16	1.15	1.00	0.98	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	69	G	0.48	0.28	3.16	1.15	1.03	0.98	75.07	5.52	-0.40
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	70	G	0.50	0.46	3.16	1.15	1.05	0.98	75.07	5.52	-0.40
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	71	G	0.52	0.87	3.16	1.27	1.06	0.98	75.07	5.52	-0.40
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	72	A	0.55	1.51	5.59	1.29	1.07	0.92	89.09	5.57	1.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	73	D	0.59	2.21	5.51	1.21	1.07	0.93	133.10	3.80	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	74	P	0.62	3.87	5.56	1.13	1.08	0.95	115.13	5.96	-1.60
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	75	E	0.63	5.13	5.67	1.11	1.09	0.97	147.13	4.00	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	76	T	0.65	4.11	6.30	1.22	1.10	0.96	119.12	5.19	-0.70
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	77	Q	0.68	3.62	5.17	1.14	1.11	1.00	146.15	5.52	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	78	S	0.68	2.80	5.80	1.13	1.09	0.99	105.09	5.24	-0.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	79	S	0.68	1.96	4.99	1.12	1.05	1.02	105.09	5.24	-0.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	80	H	0.67	1.19	2.81	1.12	1.01	1.02	155.16	6.74	-3.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	81	S	0.65	1.48	3.39	1.19	0.97	0.99	105.09	5.24	-0.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	82	A	0.63	0.91	1.14	1.07	0.95	1.03	89.09	5.57	1.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	83	W	0.61	0.66	1.03	1.09	0.94	1.01	204.23	5.52	-0.90
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	84	D	0.59	0.66	1.66	1.16	0.96	1.00	133.10	3.80	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	85	L	0.55	0.66	1.03	1.05	0.98	1.00	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	86	G	0.54	0.55	-0.59	1.04	0.99	1.01	75.07	5.52	-0.40
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	87	S	0.52	0.28	-0.47	0.99	0.99	1.04	105.09	5.24	-0.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	88	A	0.48	0.30	-3.21	0.86	0.97	1.07	89.09	5.57	1.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	89	F	0.46	0.40	-0.97	0.98	0.95	1.03	165.19	5.52	2.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	90	F	0.43	0.30	-0.97	0.98	0.96	1.03	165.19	5.52	2.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	91	F	0.40	0.43	-1.16	0.92	0.98	1.02	165.19	5.52	2.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	92	S	0.37	0.34	-2.60	0.89	1.01	1.03	105.09	5.24	-0.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	93	G	0.35	0.28	-2.43	0.87	1.02	1.04	75.07	5.52	-0.40
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	94	T	0.36	0.46	-0.37	0.92	1.01	1.01	119.12	5.19	-0.70
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	95	I	0.35	0.50	1.69	0.97	0.99	0.99	131.17	5.52	4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	96	I	0.36	0.35	-0.39	0.84	0.98	1.01	131.17	5.52	4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	97	T	0.38	0.24	-0.39	0.84	0.99	1.01	119.12	5.19	-0.70
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	98	T	0.41	0.54	-1.40	0.86	0.99	1.04	119.12	5.19	-0.70
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	99	I	0.44	0.77	0.56	1.02	0.99	1.00	131.17	5.52	4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	100	G	0.48	0.85	2.70	1.17	0.99	0.95	75.07	5.52	-0.40
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	101	Y	0.52	0.44	1.43	1.11	0.98	1.02	181.19	5.52	-1.30
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	102	G	0.57	0.63	0.99	1.06	0.98	1.04	75.07	5.52	-0.40
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	103	N	0.60	0.53	0.81	1.08	0.97	1.05	132.12	5.52	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	104	V	0.60	0.66	0.60	0.99	0.96	1.05	117.15	5.49	4.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	105	A	0.62	0.96	1.61	0.97	0.96	1.02	89.09	5.57	1.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	106	L	0.62	1.00	2.23	0.95	0.98	1.02	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	107	R	0.62	1.36	1.53	0.83	1.01	1.06	174.20	9.75	-4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	108	T	0.62	1.33	2.87	0.98	1.04	0.99	119.12	5.19	-0.70
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	109	D	0.60	3.16	3.17	1.02	1.05	0.96	133.10	3.80	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	110	A	0.58	1.33	3.17	1.02	1.05	0.96	89.09	5.57	1.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	111	G	0.54	0.80	1.26	0.97	1.03	0.99	75.07	5.52	-0.40
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	112	R	0.50	0.26	0.71	1.00	1.00	1.06	174.20	9.75	-4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	113	L	0.46	0.18	-1.86	0.86	0.97	1.10	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	114	F	0.43	0.16	-3.47	0.85	0.94	1.11	165.19	5.52	2.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	115	C	0.39	0.12	-4.56	0.79	0.92	1.15	121.15	5.52	2.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	116	I	0.35	0.15	-4.86	0.75	0.90	1.17	131.17	5.52	4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	117	F	0.32	0.15	-4.86	0.75	0.89	1.17	165.19	5.52	2.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	118	Y	0.29	0.20	-4.07	0.74	0.89	1.22	181.19	5.52	-1.30
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	119	A	0.28	0.28	-3.46	0.79	0.89	1.14	89.09	5.57	1.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	120	L	0.28	0.23	-3.46	0.79	0.91	1.14	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	121	V	0.29	0.23	-1.84	0.92	0.92	1.14	117.15	5.49	4.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	122	G	0.30	0.19	-2.89	0.84	0.94	1.15	75.07	5.52	-0.40
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	123	I	0.30	0.19	-4.50	0.83	0.95	1.15	131.17	5.52	4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	124	P	0.31	0.26	-2.37	0.97	0.95	1.10	115.13	5.96	-1.60
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	125	L	0.32	0.18	-2.99	0.97	0.94	1.07	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	126	F	0.33	0.22	-5.11	0.83	0.93	1.12	165.19	5.52	2.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	127	G	0.34	0.12	-5.29	0.85	0.92	1.13	75.07	5.52	-0.40
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	128	I	0.35	0.14	-5.29	0.72	0.92	1.13	131.17	5.52	4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	129	L	0.36	0.16	-3.16	0.86	0.92	1.08	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	130	L	0.38	0.12	-2.37	0.85	0.93	1.12	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	131	A	0.40	0.17	-2.37	0.85	0.94	1.12	89.09	5.57	1.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	132	G	0.44	0.35	0.20	0.99	0.96	1.08	75.07	5.52	-0.40
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	133	V	0.46	0.82	2.11	1.04	0.98	1.03	117.15	5.49	4.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	134	G	0.48	0.67	2.11	1.04	1.00	1.03	75.07	5.52	-0.40
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	135	D	0.50	0.67	2.63	1.17	1.01	1.00	133.10	3.80	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	136	R	0.52	1.21	2.74	1.15	1.03	1.02	174.20	9.75	-4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	137	L	0.54	1.64	4.20	1.28	1.04	0.97	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	138	G	0.55	0.81	2.07	1.14	1.05	1.02	75.07	5.52	-0.40
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	139	S	0.56	0.81	1.24	1.07	1.05	1.02	105.09	5.24	-0.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	140	S	0.56	1.34	0.94	1.07	1.03	1.05	105.09	5.24	-0.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	141	L	0.55	1.34	3.07	1.21	1.00	1.00	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	142	R	0.54	0.70	1.11	1.05	0.97	1.04	174.20	9.75	-4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	143	H	0.55	0.52	1.00	1.07	0.96	1.02	155.16	6.74	-3.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	144	G	0.55	0.85	0.37	1.00	0.95	1.03	75.07	5.52	-0.40
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	145	I	0.56	0.31	0.54	0.99	0.95	1.02	131.17	5.52	4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	146	G	0.56	0.39	1.06	0.96	0.94	1.02	75.07	5.52	-0.40
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	147	H	0.57	0.40	1.06	0.92	0.94	1.01	155.16	6.74	-3.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	148	I	0.59	0.40	-0.90	0.76	0.93	1.05	131.17	5.52	4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	149	E	0.59	0.35	-1.07	0.78	0.92	1.04	147.13	4.00	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	150	A	0.60	0.21	-3.20	0.64	0.92	1.10	89.09	5.57	1.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	151	I	0.62	0.60	-2.69	0.65	0.93	1.07	131.17	5.52	4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	152	F	0.63	0.36	-2.97	0.72	0.94	1.03	165.19	5.52	2.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	153	L	0.64	0.49	-3.79	0.75	0.95	1.07	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	154	K	0.64	0.52	-4.61	0.73	0.95	1.11	146.19	8.75	-3.90
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	155	W	0.64	0.93	-3.17	0.88	0.96	1.10	204.23	5.52	-0.90
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	156	H	0.64	1.74	-1.56	1.01	0.96	1.10	155.16	6.74	-3.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	157	V	0.64	1.51	0.87	1.03	0.98	1.04	117.15	5.49	4.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	158	P	0.65	1.18	-1.26	0.97	1.00	1.09	115.13	5.96	-1.60
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	159	P	0.67	0.64	-0.36	0.90	1.01	1.16	115.13	5.96	-1.60
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	160	E	0.65	1.70	-0.06	0.90	1.00	1.12	147.13	4.00	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	161	L	0.65	0.82	-0.06	0.90	0.98	1.12	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	162	V	0.63	0.44	-1.67	0.77	0.95	1.15	117.15	5.49	4.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	163	R	0.62	0.34	-1.04	0.76	0.94	1.14	174.20	9.75	-4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	164	V	0.60	0.41	-1.86	0.75	0.93	1.17	117.15	5.49	4.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	165	L	0.58	0.55	-1.14	0.75	0.93	1.11	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	166	S	0.56	0.23	-1.93	0.76	0.92	1.09	105.09	5.24	-0.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	167	A	0.55	0.27	-3.84	0.71	0.91	1.13	89.09	5.57	1.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	168	M	0.52	0.27	-4.63	0.72	0.90	1.11	149.21	5.28	1.90
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	169	L	0.53	0.17	-4.63	0.72	0.90	1.11	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	170	F	0.53	0.12	-6.70	0.59	0.90	1.13	165.19	5.52	2.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	171	L	0.53	0.12	-6.19	0.71	0.91	1.10	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	172	L	0.55	0.07	-5.39	0.80	0.91	1.18	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	173	I	0.56	0.07	-5.39	0.80	0.91	1.18	131.17	5.52	4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	174	G	0.56	0.07	-5.39	0.80	0.91	1.21	75.07	5.52	-0.40
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	175	C	0.55	0.07	-5.39	0.80	0.91	1.18	121.15	5.52	2.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	176	L	0.52	0.08	-4.60	0.79	0.91	1.20	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	177	L	0.49	0.07	-4.77	0.80	0.92	1.22	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	178	F	0.45	0.18	-4.84	0.72	0.93	1.22	165.19	5.52	2.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	179	V	0.43	0.33	-4.74	0.76	0.95	1.17	117.15	5.49	4.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	180	L	0.41	0.58	-2.69	0.82	0.98	1.12	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	181	T	0.39	0.58	-2.69	0.82	1.00	1.10	119.12	5.19	-0.70
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	182	P	0.39	0.58	-1.90	0.80	1.01	1.14	115.13	5.96	-1.60
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	183	T	0.39	0.61	-2.69	0.82	0.99	1.10	119.12	5.19	-0.70
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	184	F	0.41	0.23	-1.17	0.90	0.97	1.12	165.19	5.52	2.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	185	V	0.44	0.23	-2.19	0.93	0.94	1.16	117.15	5.49	4.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	186	F	0.47	0.16	-3.09	0.80	0.91	1.12	165.19	5.52	2.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	187	C	0.50	0.32	-2.71	0.77	0.90	1.12	121.15	5.52	2.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	188	Y	0.52	0.71	0.03	0.89	0.91	1.08	181.19	5.52	-1.30
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	189	M	0.54	0.87	-0.87	0.96	0.93	1.01	149.21	5.28	1.90
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	190	E	0.54	2.16	1.37	1.07	0.97	1.00	147.13	4.00	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	191	D	0.53	2.76	1.99	1.05	1.00	0.93	133.10	3.80	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	192	W	0.53	2.30	0.94	0.97	1.01	0.95	204.23	5.52	-0.90
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	193	S	0.51	2.30	2.66	0.99	1.02	0.95	105.09	5.24	-0.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	194	K	0.48	1.39	1.84	0.98	1.01	0.98	146.19	8.75	-3.90
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	195	L	0.45	0.93	-0.73	0.84	0.98	1.02	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	196	E	0.41	1.08	0.43	0.86	0.95	1.06	147.13	4.00	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	197	A	0.37	0.47	-1.81	0.74	0.93	1.07	89.09	5.57	1.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	198	I	0.34	0.42	-3.16	0.67	0.90	1.14	131.17	5.52	4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	199	Y	0.30	0.17	-2.99	0.65	0.89	1.12	181.19	5.52	-1.30
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	200	F	0.28	0.13	-4.63	0.62	0.89	1.20	165.19	5.52	2.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	201	V	0.25	0.26	-4.19	0.66	0.90	1.18	117.15	5.49	4.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	202	I	0.26	0.14	-4.36	0.68	0.91	1.19	131.17	5.52	4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	203	V	0.26	0.23	-3.34	0.65	0.93	1.15	117.15	5.49	4.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	204	T	0.27	0.44	-1.29	0.71	0.95	1.13	119.12	5.19	-0.70
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	205	L	0.29	0.47	-1.29	0.71	0.98	1.13	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	206	T	0.32	0.62	0.67	0.86	1.00	1.09	119.12	5.19	-0.70
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	207	T	0.36	0.37	-0.11	0.88	1.00	1.05	119.12	5.19	-0.70
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	208	V	0.39	0.45	-0.04	0.96	0.99	1.04	117.15	5.49	4.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	209	G	0.42	0.52	2.70	1.09	0.98	0.99	75.07	5.52	-0.40
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	210	F	0.45	0.56	1.69	1.11	0.98	1.02	165.19	5.52	2.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	211	G	0.46	0.56	0.41	1.05	0.99	1.09	75.07	5.52	-0.40
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	212	D	0.48	0.58	1.24	1.07	0.99	1.04	133.10	3.80	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	213	Y	0.49	0.66	1.24	1.07	0.97	1.04	181.19	5.52	-1.30
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	214	V	0.51	0.67	2.86	1.08	0.96	1.04	117.15	5.49	4.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	215	A	0.54	0.67	3.47	1.06	0.96	1.04	89.09	5.57	1.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	216	G	0.56	0.66	2.34	1.07	0.98	1.07	75.07	5.52	-0.40
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	217	A	0.58	1.75	3.21	1.04	1.01	1.03	89.09	5.57	1.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	218	D	0.59	3.00	4.60	1.11	1.04	0.97	133.10	3.80	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	219	P	0.60	5.06	5.73	1.23	1.06	0.95	115.13	5.96	-1.60
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	220	R	0.63	6.71	5.84	1.21	1.08	0.97	174.20	9.75	-4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	221	Q	0.64	6.21	5.84	1.33	1.09	0.97	146.15	5.52	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	222	D	0.64	4.06	4.71	1.22	1.09	0.99	133.10	3.80	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	223	S	0.63	3.25	4.14	1.16	1.08	1.01	105.09	5.24	-0.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	224	P	0.60	3.25	4.40	1.17	1.05	1.03	115.13	5.96	-1.60
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	225	A	0.57	3.01	3.84	1.24	1.02	1.04	89.09	5.57	1.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	226	Y	0.54	1.85	1.10	1.12	1.01	1.09	181.19	5.52	-1.30
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	227	Q	0.51	0.89	-0.36	0.99	1.00	1.14	146.15	5.52	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	228	P	0.48	0.92	-2.09	0.91	0.98	1.12	115.13	5.96	-1.60
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	229	L	0.44	0.51	-3.70	0.90	0.96	1.12	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	230	V	0.40	0.31	-4.86	0.87	0.92	1.08	117.15	5.49	4.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	231	W	0.37	0.14	-6.86	0.80	0.89	1.10	204.23	5.52	-0.90
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	232	F	0.34	0.14	-8.47	0.67	0.87	1.13	165.19	5.52	2.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	233	W	0.31	0.16	-8.47	0.67	0.87	1.13	204.23	5.52	-0.90
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	234	I	0.29	0.15	-7.13	0.82	0.88	1.06	131.17	5.52	4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	235	L	0.29	0.14	-7.01	0.77	0.91	1.11	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	236	L	0.30	0.13	-5.40	0.77	0.92	1.10	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	237	G	0.29	0.30	-4.24	0.80	0.92	1.14	75.07	5.52	-0.40
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	238	L	0.28	0.32	-4.41	0.82	0.92	1.13	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	239	A	0.29	0.39	-2.80	0.83	0.91	1.11	89.09	5.57	1.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	240	Y	0.29	0.52	-0.56	0.95	0.90	1.07	181.19	5.52	-1.30
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	241	F	0.30	0.47	-1.90	0.80	0.91	1.15	165.19	5.52	2.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	242	A	0.33	0.38	-1.90	0.80	0.92	1.15	89.09	5.57	1.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	243	S	0.35	0.35	-1.46	0.84	0.93	1.12	105.09	5.24	-0.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	244	V	0.35	0.59	-0.44	0.81	0.96	1.09	117.15	5.49	4.20
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	245	L	0.34	0.41	-0.27	0.80	0.98	1.10	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	246	T	0.36	0.30	0.24	0.92	1.00	1.07	119.12	5.19	-0.70
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	247	T	0.39	0.66	0.31	0.94	1.02	1.04	119.12	5.19	-0.70
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	248	I	0.40	0.84	-0.59	1.01	1.02	0.97	131.17	5.52	4.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	249	G	0.41	0.48	-0.59	1.01	1.01	0.97	75.07	5.52	-0.40
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	250	N	0.37	0.65	-0.73	1.01	0.00	0.96	132.12	5.52	-3.50
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	251	W	0.33	0.00	0.00	0.00	0.00	0.00	204.23	5.52	-0.90
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	252	L	0.28	0.00	0.00	0.00	0.00	0.00	131.17	5.52	3.80
4WFF_B Chain B of Human TRAAK K+ channel in a K+ bound nonconductive conformation	253	R	0.24	0.00	0.00	0.00	0.00	0.00	174.20	9.75	-4.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	1	C	0.24	0.00	0.00	0.00	0.00	0.00	121.15	5.52	2.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	2	D	0.29	0.00	0.00	0.00	0.00	0.00	133.10	3.80	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	3	A	0.34	0.12	0.00	0.00	0.00	0.00	89.09	5.57	1.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	4	F	0.40	0.32	1.64	0.99	0.95	1.09	165.19	5.52	2.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	5	V	0.45	0.20	0.01	0.96	0.96	1.01	117.15	5.49	4.20
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	6	G	0.47	0.40	-0.60	0.89	0.99	1.02	75.07	5.52	-0.40
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	7	T	0.49	0.38	-2.21	0.88	1.00	1.05	119.12	5.19	-0.70
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	8	W	0.50	0.38	-1.43	0.87	0.99	1.09	204.23	5.52	-0.90
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	9	K	0.52	0.52	0.03	1.00	1.00	1.04	146.19	8.75	-3.90
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	10	L	0.53	0.48	0.14	0.98	1.00	1.06	131.17	5.52	3.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	11	V	0.55	0.79	0.51	0.95	1.01	1.05	117.15	5.49	4.20
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	12	S	0.56	0.64	2.94	1.04	1.04	1.03	105.09	5.24	-0.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	13	S	0.57	0.67	0.81	0.98	1.05	1.05	105.09	5.24	-0.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	14	E	0.58	1.51	3.56	1.10	1.05	1.00	147.13	4.00	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	15	N	0.58	1.88	5.51	1.24	1.05	0.92	132.12	5.52	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	16	F	0.55	2.20	4.31	1.20	1.03	0.95	165.19	5.52	2.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	17	D	0.55	1.26	2.79	1.08	1.02	0.92	133.10	3.80	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	18	D	0.55	1.56	2.49	1.12	1.01	0.93	133.10	3.80	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	19	Y	0.54	3.13	2.60	1.00	0.99	0.94	181.19	5.52	-1.30
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	20	M	0.53	1.39	3.39	0.99	0.99	0.98	149.21	5.28	1.90
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	21	K	0.53	0.82	2.77	1.00	0.99	0.98	146.19	8.75	-3.90
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	22	E	0.52	0.39	0.81	0.86	0.99	1.06	147.13	4.00	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	23	V	0.53	0.39	1.90	0.92	0.98	1.02	117.15	5.49	4.20
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	24	G	0.54	0.17	1.19	0.92	0.97	1.06	75.07	5.52	-0.40
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	25	V	0.55	0.10	0.67	0.87	0.95	1.07	117.15	5.49	4.20
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	26	G	0.55	0.19	0.30	0.91	0.95	1.08	75.07	5.52	-0.40
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	27	F	0.54	0.38	1.43	0.97	0.96	1.01	165.19	5.52	2.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	28	A	0.54	1.02	1.43	0.89	0.98	1.02	89.09	5.57	1.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	29	T	0.52	0.77	1.43	0.89	1.00	1.02	119.12	5.19	-0.70
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	30	R	0.53	0.89	0.91	0.76	1.01	1.04	174.20	9.75	-4.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	31	K	0.52	0.88	3.04	0.90	1.01	1.01	146.19	8.75	-3.90
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	32	V	0.51	0.60	2.14	0.89	0.98	0.98	117.15	5.49	4.20
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	33	A	0.51	0.31	1.70	0.85	0.95	1.00	89.09	5.57	1.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	34	G	0.51	0.31	1.91	0.86	0.94	1.01	75.07	5.52	-0.40
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	35	M	0.50	0.65	1.40	0.93	0.94	1.03	149.21	5.28	1.90
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	36	A	0.48	1.03	2.93	1.08	0.97	0.94	89.09	5.57	1.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	37	K	0.47	1.03	2.03	1.07	0.99	0.91	146.19	8.75	-3.90
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	38	P	0.46	0.73	0.07	0.92	0.99	0.95	115.13	5.96	-1.60
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	39	N	0.45	0.50	-0.47	0.90	0.97	0.99	132.12	5.52	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	40	M	0.45	0.34	0.16	1.01	0.94	0.99	149.21	5.28	1.90
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	41	I	0.45	0.16	-1.19	0.94	0.92	1.05	131.17	5.52	4.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	42	I	0.45	0.16	-0.49	0.94	0.92	1.01	131.17	5.52	4.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	43	S	0.46	0.16	-0.67	0.94	0.94	1.02	105.09	5.24	-0.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	44	V	0.47	0.39	1.36	1.06	0.98	1.03	117.15	5.49	4.20
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	45	N	0.47	0.46	1.19	1.08	1.02	1.04	132.12	5.52	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	46	G	0.47	0.25	1.80	1.09	1.04	1.08	75.07	5.52	-0.40
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	47	D	0.47	0.49	1.61	1.02	1.03	1.06	133.10	3.80	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	48	L	0.47	0.21	1.00	1.01	1.00	1.03	131.17	5.52	3.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	49	V	0.46	0.42	0.60	0.93	0.98	1.04	117.15	5.49	4.20
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	50	T	0.46	0.34	0.71	0.91	0.98	1.06	119.12	5.19	-0.70
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	51	I	0.45	0.71	0.40	0.81	1.01	1.06	131.17	5.52	4.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	52	R	0.45	1.29	2.64	0.93	1.05	1.03	174.20	9.75	-4.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	53	S	0.45	1.29	3.91	0.99	1.09	0.96	105.09	5.24	-0.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	54	E	0.47	1.59	1.86	0.94	1.09	0.99	147.13	4.00	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	55	S	0.49	1.62	3.81	1.02	1.09	0.95	105.09	5.24	-0.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	56	T	0.50	1.95	4.21	1.10	1.07	0.94	119.12	5.19	-0.70
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	57	F	0.51	1.62	4.03	1.04	1.05	0.93	165.19	5.52	2.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	58	K	0.51	2.10	4.03	1.04	1.06	0.93	146.19	8.75	-3.90
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	59	N	0.50	1.02	1.96	0.90	1.06	0.95	132.12	5.52	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	60	T	0.49	1.58	2.14	0.97	1.05	0.96	119.12	5.19	-0.70
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	61	E	0.48	0.68	2.14	0.97	1.03	0.96	147.13	4.00	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	62	I	0.47	0.85	2.14	0.97	1.00	0.96	131.17	5.52	4.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	63	S	0.46	0.49	-0.17	0.83	0.98	1.03	105.09	5.24	-0.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	64	F	0.45	0.28	-0.10	0.91	0.97	1.02	165.19	5.52	2.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	65	K	0.46	0.29	-1.74	0.88	0.97	1.10	146.19	8.75	-3.90
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	66	L	0.46	0.38	0.51	0.92	0.97	1.06	131.17	5.52	3.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	67	G	0.47	0.38	-1.73	0.80	0.96	1.07	75.07	5.52	-0.40
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	68	V	0.49	0.32	1.01	0.92	0.96	1.04	117.15	5.49	4.20
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	69	E	0.52	0.67	1.31	0.88	0.97	1.02	147.13	4.00	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	70	F	0.53	0.47	1.49	0.87	0.98	1.01	165.19	5.52	2.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	71	D	0.54	0.92	1.41	0.78	1.00	1.01	133.10	3.80	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	72	E	0.56	0.53	2.24	0.80	1.01	0.97	147.13	4.00	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	73	I	0.57	1.03	2.56	0.91	1.01	0.97	131.17	5.52	4.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	74	T	0.58	1.03	5.30	1.03	1.01	0.94	119.12	5.19	-0.70
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	75	A	0.59	1.17	4.47	0.96	1.02	0.94	89.09	5.57	1.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	76	D	0.58	3.33	4.17	1.00	1.04	0.95	133.10	3.80	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	77	D	0.56	1.71	4.79	1.00	1.04	0.98	133.10	3.80	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	78	R	0.54	3.39	4.86	1.01	1.05	0.99	174.20	9.75	-4.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	79	K	0.52	2.72	5.49	1.12	1.05	0.98	146.19	8.75	-3.90
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	80	V	0.49	1.14	2.91	0.98	1.03	1.02	117.15	5.49	4.20
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	81	K	0.48	0.41	0.34	0.83	1.02	1.06	146.19	8.75	-3.90
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	82	S	0.46	0.29	0.49	0.84	0.99	1.07	105.09	5.24	-0.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	83	I	0.43	0.33	-1.64	0.78	0.96	1.11	131.17	5.52	4.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	84	I	0.42	0.27	0.31	0.91	0.95	1.04	131.17	5.52	4.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	85	T	0.43	0.20	0.31	0.99	0.97	1.03	119.12	5.19	-0.70
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	86	L	0.43	0.28	0.20	1.01	1.00	1.01	131.17	5.52	3.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	87	D	0.43	0.41	1.64	1.04	1.03	1.00	133.10	3.80	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	88	G	0.44	0.23	1.47	1.05	1.04	1.01	75.07	5.52	-0.40
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	89	G	0.46	0.21	0.20	0.99	1.02	1.08	75.07	5.52	-0.40
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	90	A	0.46	0.22	2.37	1.04	0.99	1.05	89.09	5.57	1.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	91	L	0.47	0.16	0.41	0.91	0.96	1.12	131.17	5.52	3.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	92	V	0.49	0.29	0.46	0.82	0.94	1.14	117.15	5.49	4.20
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	93	Q	0.50	0.57	0.46	0.75	0.95	1.15	146.15	5.52	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	94	V	0.52	0.73	-1.27	0.79	0.97	1.12	117.15	5.49	4.20
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	95	Q	0.53	1.63	1.47	0.91	1.00	1.07	146.15	5.52	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	96	K	0.54	0.93	2.81	1.06	1.02	1.00	146.19	8.75	-3.90
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	97	W	0.55	2.51	2.77	1.07	1.04	0.98	204.23	5.52	-0.90
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	98	D	0.55	1.94	4.23	1.20	1.07	0.93	133.10	3.80	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	99	G	0.56	1.40	4.11	1.20	1.09	0.92	75.07	5.52	-0.40
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	100	K	0.55	1.93	4.04	1.19	1.10	0.91	146.19	8.75	-3.90
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	101	S	0.55	0.81	4.33	1.12	1.10	0.95	105.09	5.24	-0.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	102	T	0.54	1.63	3.71	1.06	1.09	0.96	119.12	5.19	-0.70
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	103	T	0.53	1.60	3.50	0.97	1.07	0.96	119.12	5.19	-0.70
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	104	I	0.52	2.39	3.50	0.97	1.06	0.96	131.17	5.52	4.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	105	K	0.52	3.24	3.17	0.90	1.05	0.94	146.19	8.75	-3.90
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	106	R	0.51	3.75	3.86	0.97	1.05	0.93	174.20	9.75	-4.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	107	K	0.51	5.29	3.93	1.06	1.06	0.93	146.19	8.75	-3.90
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	108	R	0.51	4.42	6.50	1.20	1.06	0.89	174.20	9.75	-4.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	109	D	0.50	4.51	6.50	1.20	1.07	0.89	133.10	3.80	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	110	G	0.49	1.86	4.59	1.15	1.07	0.94	75.07	5.52	-0.40
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	111	D	0.47	0.71	3.24	1.08	1.05	1.01	133.10	3.80	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	112	K	0.46	0.31	2.11	1.01	1.02	1.08	146.19	8.75	-3.90
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	113	L	0.44	0.55	1.80	0.91	0.99	1.08	131.17	5.52	3.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	114	V	0.43	0.18	1.19	0.86	0.95	1.15	117.15	5.49	4.20
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	115	V	0.43	0.07	-0.77	0.72	0.93	1.23	117.15	5.49	4.20
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	116	E	0.43	0.08	-2.19	0.66	0.91	1.21	147.13	4.00	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	117	C	0.42	0.21	-0.06	0.72	0.91	1.17	121.15	5.52	2.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	118	V	0.41	0.28	1.29	0.87	0.93	1.09	117.15	5.49	4.20
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	119	M	0.42	0.12	1.29	0.87	0.95	1.09	149.21	5.28	1.90
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	120	K	0.42	0.33	0.91	0.90	0.98	1.10	146.19	8.75	-3.90
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	121	G	0.43	0.59	1.64	0.94	1.02	1.05	75.07	5.52	-0.40
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	122	V	0.45	0.86	2.91	1.00	1.04	0.98	117.15	5.49	4.20
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	123	T	0.44	0.84	4.11	1.05	1.06	0.98	119.12	5.19	-0.70
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	124	S	0.44	0.63	2.77	0.98	1.06	1.05	105.09	5.24	-0.80
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	125	T	0.44	1.33	1.69	0.92	1.05	1.09	119.12	5.19	-0.70
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	126	R	0.45	1.59	3.33	0.95	1.02	1.01	174.20	9.75	-4.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	127	V	0.45	2.33	3.19	0.95	1.00	1.01	117.15	5.49	4.20
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	128	Y	0.40	1.63	2.56	0.84	0.00	1.02	181.19	5.52	-1.30
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	129	E	0.35	0.00	0.00	0.00	0.00	0.00	147.13	4.00	-3.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	130	R	0.31	0.00	0.00	0.00	0.00	0.00	174.20	9.75	-4.50
5C0N_A Chain A of Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes.	131	A	0.25	0.00	0.00	0.00	0.00	0.00	89.09	5.57	1.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	1	L	0.26	0.00	0.00	0.00	0.00	0.00	131.17	5.52	3.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	2	G	0.31	0.00	0.00	0.00	0.00	0.00	75.07	5.52	-0.40
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	3	S	0.37	1.28	0.00	0.00	0.00	0.00	105.09	5.24	-0.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	4	R	0.43	1.28	1.06	1.00	1.06	1.01	174.20	9.75	-4.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	5	R	0.48	1.28	1.77	1.01	1.03	0.95	174.20	9.75	-4.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	6	T	0.46	0.79	-0.36	0.87	1.00	1.00	119.12	5.19	-0.70
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	7	L	0.47	0.33	-2.60	0.75	0.96	1.03	131.17	5.52	3.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	8	M	0.47	0.17	-2.90	0.71	0.92	1.06	149.21	5.28	1.90
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	9	L	0.44	0.21	-2.64	0.71	0.91	1.08	131.17	5.52	3.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	10	L	0.46	0.25	-3.99	0.66	0.91	1.07	131.17	5.52	3.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	11	A	0.47	0.49	-2.07	0.71	0.92	1.01	89.09	5.57	1.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	12	Q	0.48	1.18	-0.66	0.77	0.94	1.03	146.15	5.52	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	13	M	0.49	1.01	-0.49	0.75	0.97	1.02	149.21	5.28	1.90
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	14	R	0.51	1.33	1.76	0.87	0.99	0.98	174.20	9.75	-4.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	15	K	0.54	0.64	0.14	0.86	1.00	1.01	146.19	8.75	-3.90
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	16	I	0.55	0.56	-2.03	0.81	0.99	1.02	131.17	5.52	4.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	17	S	0.55	0.38	-0.50	0.93	0.97	1.05	105.09	5.24	-0.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	18	L	0.59	0.10	-0.90	0.96	0.95	1.12	131.17	5.52	3.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	19	F	0.58	0.12	-3.03	0.90	0.93	1.17	165.19	5.52	2.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	20	S	0.57	0.18	-1.07	0.98	0.93	1.14	105.09	5.24	-0.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	21	C	0.57	0.36	-0.57	0.98	0.95	1.12	121.15	5.52	2.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	22	L	0.58	0.82	1.34	1.03	0.97	1.06	131.17	5.52	3.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	23	K	0.58	0.83	2.96	1.08	1.00	1.06	146.19	8.75	-3.90
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	24	D	0.56	2.59	3.46	1.09	1.01	1.04	133.10	3.80	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	25	R	0.57	2.72	1.94	1.00	1.00	1.00	174.20	9.75	-4.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	26	H	0.57	1.35	4.07	1.14	0.98	0.94	155.16	6.74	-3.20
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	27	D	0.56	0.70	1.94	1.08	0.96	0.97	133.10	3.80	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	28	F	0.55	0.55	0.81	1.09	0.95	0.99	165.19	5.52	2.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	29	G	0.55	0.70	1.07	1.10	0.97	1.02	75.07	5.52	-0.40
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	30	F	0.54	0.73	1.89	1.07	1.00	0.98	165.19	5.52	2.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	31	P	0.53	1.46	1.57	0.96	1.04	0.98	115.13	5.96	-1.60
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	32	Q	0.54	1.27	1.57	0.96	1.06	0.98	146.15	5.52	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	33	E	0.55	1.46	1.57	0.96	1.06	0.98	147.13	4.00	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	34	E	0.56	1.52	3.89	1.10	1.05	0.93	147.13	4.00	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	35	F	0.58	1.52	4.44	1.02	1.04	0.92	165.19	5.52	2.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	36	G	0.60	0.76	2.27	0.97	1.03	0.94	75.07	5.52	-0.40
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	37	N	0.60	0.76	2.01	1.00	1.03	0.96	132.12	5.52	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	38	Q	0.61	1.75	1.71	1.04	1.03	0.97	146.15	5.52	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	39	F	0.61	1.79	3.33	1.05	1.02	0.97	165.19	5.52	2.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	40	Q	0.60	1.92	3.63	0.93	1.03	0.96	146.15	5.52	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	41	K	0.57	1.60	3.37	0.85	1.03	0.98	146.19	8.75	-3.90
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	42	A	0.55	1.30	1.37	0.77	1.04	1.00	89.09	5.57	1.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	43	E	0.51	1.16	2.99	0.91	1.03	1.00	147.13	4.00	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	44	T	0.46	0.43	1.60	0.84	1.02	1.05	119.12	5.19	-0.70
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	45	I	0.44	0.35	-0.53	0.78	0.99	1.10	131.17	5.52	4.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	46	P	0.41	0.28	-0.53	0.82	0.97	1.10	115.13	5.96	-1.60
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	47	V	0.38	0.33	-0.53	0.82	0.95	1.10	117.15	5.49	4.20
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	48	L	0.35	0.47	-1.87	0.77	0.93	1.09	131.17	5.52	3.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	49	H	0.34	0.21	-1.87	0.77	0.92	1.09	155.16	6.74	-3.20
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	50	E	0.35	0.49	-1.31	0.69	0.92	1.08	147.13	4.00	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	51	M	0.34	1.04	0.07	0.76	0.93	1.03	149.21	5.28	1.90
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	52	I	0.36	0.53	0.24	0.74	0.94	1.02	131.17	5.52	4.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	53	Q	0.39	0.27	-1.37	0.69	0.95	1.01	146.15	5.52	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	54	Q	0.38	0.43	-1.49	0.81	0.95	1.00	146.15	5.52	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	55	I	0.38	0.51	-2.20	0.81	0.95	1.06	131.17	5.52	4.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	56	F	0.41	0.26	-2.37	0.83	0.94	1.06	165.19	5.52	2.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	57	N	0.44	0.20	-2.30	0.89	0.94	1.06	132.12	5.52	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	58	L	0.46	0.41	-2.41	0.89	0.95	1.04	131.17	5.52	3.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	59	F	0.49	0.94	-0.46	0.96	0.98	1.01	165.19	5.52	2.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	60	S	0.54	0.98	2.29	1.09	1.01	0.98	105.09	5.24	-0.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	61	T	0.56	1.59	2.21	1.07	1.05	1.01	119.12	5.19	-0.70
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	62	K	0.58	2.46	4.46	1.19	1.07	0.98	146.19	8.75	-3.90
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	63	D	0.60	1.85	6.07	1.20	1.07	0.97	133.10	3.80	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	64	S	0.62	1.30	5.44	1.09	1.06	0.98	105.09	5.24	-0.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	65	S	0.62	0.68	3.27	1.09	1.02	0.98	105.09	5.24	-0.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	66	A	0.63	0.68	3.89	1.15	0.99	0.97	89.09	5.57	1.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	67	A	0.62	0.88	3.57	1.05	0.98	0.97	89.09	5.57	1.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	68	W	0.59	0.95	3.39	0.98	0.99	0.95	204.23	5.52	-0.90
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	69	D	0.56	0.77	1.14	0.86	1.01	0.99	133.10	3.80	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	70	E	0.53	0.63	-0.47	0.85	1.03	1.01	147.13	4.00	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	71	T	0.52	1.00	0.66	0.97	1.03	0.98	119.12	5.19	-0.70
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	72	L	0.48	1.20	2.90	0.97	1.03	0.99	131.17	5.52	3.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	73	L	0.48	0.60	0.16	0.85	1.02	1.02	131.17	5.52	3.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	74	D	0.47	0.65	-1.23	0.91	1.01	1.07	133.10	3.80	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	75	K	0.45	1.14	-1.23	0.91	1.01	1.07	146.19	8.75	-3.90
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	76	F	0.42	2.40	1.20	0.93	1.00	1.01	165.19	5.52	2.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	77	Y	0.43	1.18	1.20	0.93	0.99	1.01	181.19	5.52	-1.30
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	78	T	0.44	0.93	-0.50	0.88	0.99	1.05	119.12	5.19	-0.70
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	79	E	0.44	1.85	-0.46	0.88	0.99	1.06	147.13	4.00	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	80	L	0.43	2.05	1.71	0.93	0.99	1.05	131.17	5.52	3.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	81	Y	0.46	1.17	0.67	0.85	0.99	1.06	181.19	5.52	-1.30
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	82	Q	0.47	1.09	0.93	0.94	0.99	1.05	146.15	5.52	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	83	Q	0.46	2.20	1.24	1.04	1.00	1.05	146.15	5.52	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	84	L	0.48	1.16	1.24	1.04	1.01	1.05	131.17	5.52	3.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	85	N	0.51	1.16	2.63	0.99	1.01	1.00	132.12	5.52	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	86	D	0.48	0.68	2.07	0.94	1.00	1.01	133.10	3.80	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	87	L	0.48	0.44	1.41	0.97	0.98	1.07	131.17	5.52	3.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	88	E	0.48	0.20	2.20	0.96	0.96	1.09	147.13	4.00	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	89	A	0.50	0.09	0.06	0.80	0.94	1.14	89.09	5.57	1.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	90	C	0.50	0.18	-0.51	0.73	0.93	1.16	121.15	5.52	2.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	91	V	0.51	0.10	1.61	0.87	0.94	1.11	117.15	5.49	4.20
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	92	I	0.54	0.10	-0.10	0.85	0.95	1.10	131.17	5.52	4.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	93	Q	0.53	0.37	0.41	0.90	0.98	1.08	146.15	5.52	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	94	G	0.54	0.87	1.33	0.84	1.00	1.00	75.07	5.52	-0.40
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	95	M	0.56	2.08	3.29	0.97	1.02	0.93	149.21	5.28	1.90
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	96	K	0.57	1.61	5.36	1.11	1.04	0.91	146.19	8.75	-3.90
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	97	E	0.57	1.14	3.36	1.04	1.04	0.93	147.13	4.00	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	98	D	0.56	0.95	1.23	0.90	1.02	0.98	133.10	3.80	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	99	S	0.53	0.48	2.13	0.91	1.00	1.02	105.09	5.24	-0.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	100	I	0.52	0.21	0.79	0.84	0.96	1.08	131.17	5.52	4.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	101	L	0.53	0.24	0.27	0.87	0.94	1.09	131.17	5.52	3.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	102	A	0.51	0.36	-0.34	0.80	0.94	1.09	89.09	5.57	1.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	103	V	0.49	0.80	-1.54	0.76	0.96	1.12	117.15	5.49	4.20
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	104	R	0.48	0.84	-1.71	0.78	0.98	1.11	174.20	9.75	-4.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	105	K	0.48	1.45	0.46	0.83	0.99	1.07	146.19	8.75	-3.90
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	106	Y	0.46	3.82	0.76	0.88	0.99	1.05	181.19	5.52	-1.30
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	107	F	0.46	1.37	0.14	0.87	0.99	1.01	165.19	5.52	2.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	108	Q	0.49	0.99	0.29	0.87	0.99	1.02	146.15	5.52	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	109	R	0.48	0.52	-1.84	0.81	0.99	1.06	174.20	9.75	-4.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	110	I	0.44	0.94	-1.84	0.81	0.98	1.06	131.17	5.52	4.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	111	T	0.44	0.45	-1.84	0.81	0.96	1.09	119.12	5.19	-0.70
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	112	L	0.47	0.46	-1.89	0.82	0.95	1.08	131.17	5.52	3.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	113	Y	0.48	1.13	-1.37	0.79	0.95	1.07	181.19	5.52	-1.30
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	114	L	0.47	1.56	0.59	0.86	0.98	1.04	131.17	5.52	3.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	115	K	0.50	3.79	0.66	0.87	1.02	1.04	146.19	8.75	-3.90
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	116	E	0.49	3.79	1.70	0.95	1.05	1.03	147.13	4.00	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	117	K	0.48	6.16	2.90	0.99	1.06	1.01	146.19	8.75	-3.90
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	118	K	0.48	4.76	4.51	1.12	1.06	0.98	146.19	8.75	-3.90
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	119	Y	0.49	1.47	3.90	1.15	1.04	1.05	181.19	5.52	-1.30
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	120	S	0.48	0.74	3.09	1.14	1.01	1.08	105.09	5.24	-0.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	121	P	0.46	0.39	0.84	1.13	0.99	1.08	115.13	5.96	-1.60
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	122	C	0.45	0.43	1.14	1.09	0.95	1.07	121.15	5.52	2.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	123	A	0.41	0.24	0.89	1.00	0.94	1.10	89.09	5.57	1.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	124	W	0.40	0.11	-0.57	0.87	0.92	1.15	204.23	5.52	-0.90
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	125	E	0.39	0.42	-0.27	0.79	0.92	1.12	147.13	4.00	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	126	V	0.38	0.42	-0.17	0.71	0.93	1.07	117.15	5.49	4.20
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	127	V	0.36	0.69	0.64	0.72	0.94	1.04	117.15	5.49	4.20
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	128	R	0.39	0.28	0.93	0.65	0.94	1.08	174.20	9.75	-4.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	129	A	0.40	0.37	-0.79	0.63	0.94	1.08	89.09	5.57	1.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	130	E	0.39	0.99	0.34	0.70	0.94	1.00	147.13	4.00	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	131	I	0.37	0.67	1.80	0.83	0.94	0.95	131.17	5.52	4.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	132	M	0.40	0.58	-0.11	0.78	0.95	0.98	149.21	5.28	1.90
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	133	R	0.41	0.45	0.51	0.89	0.96	0.97	174.20	9.75	-4.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	134	S	0.41	0.53	-1.91	0.87	0.97	1.03	105.09	5.24	-0.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	135	F	0.42	0.71	0.16	1.00	0.97	1.01	165.19	5.52	2.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	136	S	0.45	0.52	1.50	1.06	0.98	1.02	105.09	5.24	-0.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	137	L	0.43	0.63	1.90	1.14	0.99	1.01	131.17	5.52	3.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	138	S	0.43	0.60	-0.34	1.02	1.00	1.04	105.09	5.24	-0.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	139	T	0.45	0.78	1.83	1.08	1.02	1.03	119.12	5.19	-0.70
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	140	N	0.47	1.63	2.01	0.98	1.02	1.01	132.12	5.52	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	141	L	0.45	1.63	4.26	1.10	1.02	0.97	131.17	5.52	3.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	142	Q	0.39	0.93	2.01	0.98	0.00	1.01	146.15	5.52	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	143	E	0.36	0.00	0.00	0.00	0.00	0.00	147.13	4.00	-3.50
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	144	S	0.29	0.00	0.00	0.00	0.00	0.00	105.09	5.24	-0.80
4Z5R_A Chain A of Rontalizumab Fab bound to Interferon-a2	145	L	0.24	0.00	0.00	0.00	0.00	0.00	131.17	5.52	3.80
